Clinical trial NCT03893630
Conditions: Pre-Eclampsia
Keywords: aspirin pulsatility index doppler uterine acetylsalicylic acid preeclampsia blood pressure
Sponsor: John O'Brien, MD
Start date: 2019-04-25; Completion date: 2022-09-28
Enrollment: 208 participants; Allocation: RANDOMIZED; Intervention model: PARALLEL

Brief summary:
Endothelial dysfunction and defective placental vascularization are hypothesized to be significant causes of preeclampsia. In preeclampsia, due to vascular endothelial dysfunction, vasoconstriction and platelet activation can result in severe features which alter pregnancy outcomes. However, studies have shown that acetylsalicylic acid (Aspirin) can decrease endothelial dysfunction leading to decreased platelet aggregation which reduces adverse outcomes. The objective of our study is to determine if Aspirin has a dose-dependent response for modifying biomarkers reflective of maternal endothelial dysfunction when indicated for preeclampsia prevention in a cohort of women identified at risk for developing preeclampsia.

Pregnant women who are at risk for preeclampsia will be randomized to receive either 81mg Aspirin or 162mg Aspirin daily starting from 11-16 weeks of gestation until 36 weeks of gestation. A third, control group of women at low risk for preeclampsia will not receive aspirin. All women will be assessed with uterine artery Doppler studies and mean arterial blood pressures at three time points during pregnancy. Blood, urine, and cord blood samples will also be collected.

Detailed description:
Eligible women will be identified in the late first or early second trimesters. Once recruited, women will be randomly assigned to either 81 mg or 162 mg per day dosing schedules. The randomization scheme will vary based on the body mass index (BMI) with separate schemes for women \<=30 kg/m2 versus \>30 kg/m2. Ultrasonographic assessment of biophysical biomarkers will be obtained at 11-16 weeks, 18-22 weeks, and 28-32 weeks gestation. Biologic samples of serum and urine will be obtained at the 11-16 week and 28-32 week visit. Upon delivery, cord blood and a placental specimen will also be obtained. Medication treatment will continue until 36 weeks gestation. Pregnancy and neonatal outcome data will be recorded.

Arms: arm 1: Patients will receive standard of care. arm 2: Patients will receive low dose (81mg) acetylsalicylic acid (Aspirin). arm 3: Patients will receive low dose (162mg) acetylsalicylic acid (Aspirin).
Interventions: intervention 1: Acetylsalicylic Acid 81 mg intervention 2: Acetylsalicylic Acid 162 mg intervention 3: Control
Intervention descriptions: intervention 1: Patients will receive 81mg acetylsalicylic acid daily, initiated between 11 and 16 weeks of gestation and continued until 36 weeks of gestation. intervention 2: Patients will receive 162mg acetylsalicylic acid daily, initiated between 11 and 16 weeks of gestation and continued until 36 weeks of gestation. intervention 3: Standard of Care

Protocol documents:
Prot_SAP_000.pdf: 
Document Coversheet 
 
 Study Title: Role of ASpirin in Placental and Maternal Endothelial Cell Regulation IN Pre-
eclampsia 
Institution/Site:  
University of Kentucky 
Document (Approval/Update) Date: 
6/27/2025 
NCT Number: 
NCT03893630 
IRB Number 
47841 
Coversheet created: 
6/27/2025 
 
 


PROTOCOL TYPE (VERSION 5)
0 unresolved
comment(s)
 
IMPORTANT NOTE:
If you accidentally select the wrong IRB type or “Protocol Process Type” while your Initial Review (IR) application is in draft
form (unsubmitted), you may change your selections. Please contact the Office of Research Integrity (ORI) at 859-257-9428,
IRBsubmission@uky.edu, or request a consult to resolve any questions regarding your selections prior to submitting your
Initial Review application.
If your submitted IR application has been returned to you for requested revisions or additional information, to streamline the
review process do not make changes to your selections here unless instructed to do so by the ORI/IRB.
Changes to this section cannot be made after initial approval has been issued (the option is not available for MR or CR).
For guidance, see:
Which IRB?
Which Protocol Process Type?  
"Getting Started"
 
Which IRB
Medical
NonMedical
Protocol Process Type
Exemption
Expedited
Full
(Must be risk level 1)
 
 
The revised Common Rule expanded exemption certification category 4 for certain secondary research with
identifiable information or biospecimens. The regulations no longer require the information or biospecimens to be
existing.  For more information see the Exemption Categories Tool.
 
Section 1 Page 1 of 1
IRB Approval
4/28/2025
IRB # 47841
IRB2


EXPEDITED CERTIFICATION
0 unresolved
comment(s)
To Be Completed Only If Protocol is to Receive Expedited Review
Applicability
A. Research activities that (1) present no more than *minimal risk to human subjects, and (2) involve only procedures listed in one or
more of the following categories, may be reviewed by the IRB through the expedited review procedure authorized by 45 CFR
46.110 and 21 CFR 56.110. The activities listed should not be deemed to be of minimal risk simply because they are included on
this list. Inclusion on this list merely means that the activity is eligible for review through the expedited review procedure when the
specific circumstances of the proposed research involve no more than minimal risk to human subjects.
B. The categories in this list apply regardless of the age of subjects, except as noted.
C. The expedited review procedure may not be used where identification of the subjects and/or their responses would reasonably
place them at risk of criminal or civil liability or be damaging to the subjects’ financial standing, employability, insurability, reputation,
or be stigmatizing, unless reasonable and appropriate protections will be implemented so that risks related to invasion of privacy and
breach of confidentiality are no greater than minimal.
D. The expedited review procedure may not be used for classified research involving human subjects.
E. IRBs are reminded that the standard requirements for informed consent (or its waiver, alteration, or exception) apply regardless of
the type of review—expedited or convened—utilized by the IRB.
*“Minimal risk” means that the probability and magnitude of harm or discomfort anticipated in the research are not greater in
and of themselves from those ordinarily encountered in daily life or during the performance of routine physical or psychological
examination or tests. 45 CFR 46.102(i)
Check the appropriate categories that apply to your research project:
 Study was originally approved by the full IRB at a convened meeting.
1) Clinical studies of drugs and medical devices only when condition (a) or (b) is met.
A. Research on drugs for which an investigational new drug application is not required. (Note: Research on marketed drugs
that significantly increases the risks or decreases the acceptability of the risks associated with the use of the product is
not eligible for expedited review.)
B. Research on medical devices for which (i) an investigational device exemption application is not required*; or (ii) the
medical device is cleared/approved for marketing and the medical device is being used in accordance with its
cleared/approved labeling.**
* Study must meet one of the IDE Exempt categories listed on the Device Form Attachment. 
** An approved Device used in research according to its approved labeling is considered Exempt from IDE requirements. 
NOTE: Select Category 1 for compassionate use medical device applications or individual patient expanded access
investigational drug applications for which FDA has waived the requirement for full review.
2) Collection of blood samples by finger stick, heel stick, ear stick, or venipuncture as follows:
A. From healthy, nonpregnant adults who weigh at least 110 pounds. For these subjects, the amounts drawn may not
exceed 550 ml in an 8 week period and collection may not occur more frequently than 2 times per week; or
B. From other adults and children* considering the age, weight, and health of the subjects, the collection procedure, the
amount of blood to be collected, and the frequency with which it will be collected. For these subjects, the amount drawn
may not exceed the lesser of 50 ml or 3 ml per kg in an 8 week period and collection may not occur more frequently than
2 times per week.
NOTE: Intravenous (IV), Port, Central, or any other lines are NOT eligible under this category even if the research involves
“minimal risk”.
*In Kentucky, “child/children” refers to all individuals less than 18 years of age unless the individual(s) is/are legally
emancipated. (See Informed Consent SOP for discussion of “Emancipated Individuals” under Kentucky state law.)
Individuals less than 18 years of age who are not emancipated meet the federal definition for “child” (e.g., DHHS, FDA, and
U.S. Department of Education). Children are defined in the HHS regulations as “persons who have not attained the legal age
for consent to treatments or procedures involved in the research, under the applicable law of the jurisdiction in which the
research will be conducted.” If conducting research outside the state of Kentucky, you are responsible for complying with
applicable state law.
3) Prospective collection of biological specimens for research purposes by noninvasive means. Examples:
Section 2 Page 1 of 2
47841


A. Hair and nail clippings in a nondisfiguring manner;
B. Deciduous teeth at time of exfoliation or if routine patient care indicates a need for extraction;
C. Permanent teeth if routine patient care indicates a need for extraction;
D. Excreta and external secretions (including sweat);
E. Uncannulated saliva collected either in an unstimulated fashion or stimulated by chewing gumbase or wax or by applying
a dilute citric solution to the tongue;
F. placenta removed at delivery;
G. Amniotic fluid obtained at the time of rupture of the membrane prior to or during labor;
H. Supra- and subgingival dental plaque and calculus, provided the collection procedure is not more invasive than routine
prophylactic scaling of the teeth and the process is accomplished in accordance with accepted prophylactic techniques;
I. Mucosal and skin cells collected by buccal scraping or swab, skin swab, or mouth washings;
J. Sputum collected after saline mist nebulization.
4) Collection of data through noninvasive procedures (not involving general anesthesia or sedation) routinely employed in
clinical practice, excluding procedures involving x-rays or microwaves. Where medical devices are employed, they must be
cleared/approved for marketing. (Studies intended to evaluate the safety and effectiveness of the medical device are not
generally eligible for expedited review, including studies of cleared medical devices for new indications.) Examples:
A. Physical sensors that are applied either to the surface of the body or at a distance and do not involve input of significant
amounts of energy into the subject or an invasion of the subject’s privacy;
B. Weighing or testing sensory acuity;
C. Magnetic resonance imaging;
D. electrocardiography, electroencephalography, thermography, detection of naturally occurring radioactivity,
electroretinography, ultrasound, diagnostic infrared imaging, doppler blood flow, and echocardiography;
E. moderate exercise, muscular strength testing, body composition assessment, and flexibility testing where appropriate
given the age, weight, and health of the individual.
5) Research involving materials (data, documents, records, or specimens) that have been or will be collected solely for non-
research purposes (such as medical treatment or diagnosis) as well as research involving existing information or specimens that
were previously collected for research purposes, provided they were not collected for the currently proposed research. (Note:
Some research in this category may qualify for Exempt review. This listing refers only to research that is not exempt.) 
(Note: If submission includes materials previously collected for either non-research or research purposes in a protocol for which
IRB approval expired, you may check Category 5. However, a separate category must also be selected for prospective collection
of data/specimens obtained solely for research purposes)
6) Collection of data from voice, video, digital, or image recordings made for research purposes.
7) Research on individual or group characteristics or behavior (including, but not limited to, research on perception, cognition,
motivation, identity, language, communication, cultural beliefs or practices, and social behavior) or research employing survey,
interview, oral history, focus group, program evaluation, human factors evaluation, or quality assurance methodologies. (Note:
Some research in this category may be exempt from the HHS regulations for the protection of human subjects. This listing refers
only to research that is not exempt.)
Section 2 Page 2 of 2
47841


MODIFICATION REQUEST SECTION
0 unresolved
comment(s)
*** If this modification changes the scope of your activities to include COVID-19 related research, please insert “COVID19” at
the start of your Project and Short Titles.***
Select One:
This modification does not increase risk to study participants.
This modification may or will increase risk to study participants.
Is this modification request due to an Unanticipated Problem/Adverse Event, or Protocol Violation?
Yes
No
In your professional opinion, does this modification involve information that might relate to a subject’s willingness to continue to
take part in the research?
Yes
No
If yes, state how the information will be communicated to subjects (i.e., re-consent, send letter, etc.):
For each proposed modification, include a justification.
Example: Jane Doe, MD, is being added as co-investigator because she has expertise with the subjects on this protocol.
She has completed human subject protections training, and is authorized to obtain consent.
Greg Hawk , Katie Thompson and Tori Stanton are being added as
project assistance for data analysis because they have expertise with
the subjects on this protocol.
Section 3 Page 1 of 1
47841


PROJECT INFORMATION
0 unresolved
comment(s)
Title of Project: (Use the exact title listed in the grant/contract application, if applicable). 
If your research investigates any aspect of COVID-19, please include "COVID19" at the beginning of your Project Title and Short Title 
Role of aspirin in maternal endothelial dysfunction and
uterine artery blood flow in women at risk for preeclampsia
Short Title Description 
Please use a few key words to easily identify your study - this text will be displayed in the Dashboard listing for your study.
ASPERIN Trial
Anticipated Ending Date of Research Project: 
Maximum number of human subjects (or records/specimens to be reviewed) 
209
After approval, will the study be open to enrollment of new subjects or new data/specimen collection? 
Yes
No
Are you requesting that the UK IRB serve as the lead IRB for a multi-site study, OR that the UK IRB defer review to another IRB? [Click
here for "IRB Reliance" help]
Yes
No
If "Yes," before completing your IRB application, fill out the Reliance Request Form and submit it to irbreliance@uky.edu.
3/31/2026
Section 4 Page 1 of 1
47841


PI CONTACT INFORMATION
0 unresolved
comment(s)
Principal Investigator (PI) role for E-IRB access
The PI is the individual holding primary responsibility on the research project with the following permissions on the E-IRB application:
1. Read; 
2. write/edit;
3. receive communications; and 
4. submit to the IRB (IR, CR, MR, Other Review*).
If research is being submitted to or supported by an extramural funding agency such as NIH, a private foundation or a
pharmaceutical/manufacturing company, the PI listed on the grant application or the drug protocol must be listed as PI here. 
Please fill in any blank fields with the appropriate contact information (gray shaded fields are not editable). Required fields left blank will
be highlighted in pink after you click "Save".
To change home and work addresses, go to myUK and update using the Employee Self Service (ESS) portal. If name has changed,
the individual with the name change will need to submit a 'Name Change Form' to the Human Resources Benefits Office for entering
into SAP. The new name will need to be associated with the individual's Link Blue ID in SAP before the change is reflected in E-IRB.
Contact the HR Benefits Office for additional information.
The Principal Investigator's (PI) contact information is filled in automatically based on who logged in to create the application.
If you are not the Principal Investigator, do NOT add yourself as study personnel.
To change the PI contact information on an application in Researcher edit status:
click "Change Principal Investigator";
search for the PI's name using the search feature;
click "Select" by the name of the Principal Investigator, then "Save Contact Information".
You will automatically be added as study personnel with editing permissions to continue editing the application.
Change Principal Investigator:
First Name: John
Room# &
Bldg: C374 A B CHANDLER
MEDICAL CENTER
Last Name: O'Brien
Speed
Sort#: 
405360293
Middle Name Michael
Department:
Dept Code: 7H500
 
PI’s
Employee/Student
ID#:
10796931
Rank: 
Professor
 
PI's Telephone #: 8592180765
Degree: MD
PI's e-mail
address: john.obrien2@uky.edu
PI's FAX
Number: 859-218-7577
PI is R.N. 
Yes
No
HSP Trained: Yes
HSP Trained
Date: 7/31/2023
RCR Trained: Yes
Do you, the PI/researcher, have a significant financial interest related to your responsibilities at the University of Kentucky (that
requires disclosure per the UK administrative regulation 7:2)?
Yes
No
Obstetrics & Gynecology - 7H… 
Section 5 Page 1 of 2
47841


Section 5 Page 2 of 2
47841


RISK LEVEL
0 unresolved
comment(s)
Indicate which of the categories listed below accurately describes this protocol
(Risk Level 1) Not greater than minimal risk
(Risk Level 2) Greater than minimal risk, but presenting the prospect of direct benefit to individual subjects
(Risk Level 3) Greater than minimal risk, no prospect of direct benefit to individual subjects, but likely to yield generalizable
knowledge about the subject's disorder or condition.
(Risk Level 4) Research not otherwise approvable which presents an opportunity to understand, prevent, or alleviate a serious
problem affecting the health or welfare of subjects.
*“Minimal risk” means that the probability and magnitude of harm or discomfort anticipated in the research are not greater in and of
themselves from those ordinarily encountered in daily life or during the performance of routine physical or psychological
examination or tests.
***For Expedited and Exempt Applications, the research activities must be Risk Level 1 (no more than minimal risk to
human subjects).***
Refer to UK's guidance document on assessing the research risk for additional information.
Section 6 Page 1 of 1
47841


SUBJECT DEMOGRAPHICS
0 unresolved comment(s)
Age level of human subjects: (i.e., 6 mths.; 2yrs., etc..) 18 to 45
Study Population:
Describe the characteristics of the subject population, including age range, gender, ethnic background and health status. Identify the criteria for inclusion and
exclusion. 
Provide the following information:
A description of the subject selection criteria and rationale for selection in terms of the scientific objectives and proposed study design;
A compelling rationale for proposed exclusion of any sex/gender or racial/ethnic group;
Justification for the inclusion of vulnerable groups such as children, prisoners, adults with impaired consent capacity, or others who may be vulnerable to
coercion or undue influence.
Please consider these resources: 
NIH Diversity Policy 
FDA Diversity Guidance 
The study population will include pregnant women between the ages 18 and 45 years enrolled as cases and controls. Women at high risk for preeclampsia will
be enrolled as cases and those without risk factors for preeclampsia will be approached to serve as a control population. Approximately 250 eligible women
will be enrolled in this study (50 in the normal control arm, 100 in the low dose 81 mg per day arm, and 100 in the 162 mg per day arm). Eligible patients will be
recruited from UK clinics and the UK Good Samaritan ultrasound unit at the time of their scheduled prenatal visits or ultrasound appointments. Women who
plan to deliver at University of Kentucky Chandler Hospital will be approached for enrollment. 
The risk factor assessment to screen women at high risk for preeclampsia include: 
1. History of preterm preeclampsia, especially when accompanied by an adverse outcome
2. Chronic hypertension 
3. Type 1 and Type 2 diabetes 
4. Renal diseases 
5. Autoimmune disease 
Exclusion criteria include: 
1. Pregnant women younger than 18 years or older than 45 years
2. Multiple gestations 
3. History of allergy (urticaria or anaphylaxis) to aspirin or aspirin related products asthma that worsens after aspirin use
4. Patients with gastrointestinal or genitourinary bleeding
5. Patients with peptic ulcer disease
6. Patients with severe liver dysfunction 
7. Patients who have undergone bypass surgery
8. Patients on anticoagulant medication(s)
9. Women with anomalous fetus 
Recruitment and data collection is expected to last throughout 2018-2022 academic years. Data analysis is expected to be accomplished during 2019-2022
academic years.
Attachments
Indicate the targeted/planned enrollment of the following members of minority groups and their subpopulations. Possible demographic
sources: Census Regional Analyst Edition, Kentucky Race/Ethnic Table, Kentucky Population Data. 
(Please note: The IRB will expect this information to be reported at Continuation Review time for Pre-2019 FDA-regulated
Expedited review and Full review applications):
Participant Demographics
Cisgender Man 
Cisgender Woman 
TGNB/TGE 
Unknown/Not Reported
American
Indian/Alaskan
Native:
Asian:
Black/African
American:
Latinx:
Native
Hawaiian/Pacific
Islander:
White:
American
Arab/Middle
Eastern/North
African:
Indigenous
People Around
0
2
0
10
0
35
0
25
0
2
0
166
1
1
Section 7 Page 1 of 3
47841


the World:
More than One
Race:
Unknown or Not
Reported:
 
If unknown, please explain why:
Indicate the categories of subjects and controls to be included in the study. You may be required to complete additional forms depending on
the subject categories which apply to your research. If the study does not involve direct intervention or direct interaction with subjects, (e.g.,
record-review research, outcomes registries), do not check populations which the research does not specifically target. For example: a large
record review of a diverse population may incidentally include a prisoner or an international citizen, but you should not check those categories
if the focus of the study has nothing to do with that status.
Check All That Apply (at least one item must be selected)
Children (individuals under age
18)
Wards of the State (Children)
Emancipated Minors
Students
College of Medicine Students
UK Medical Center Residents or
House Officers
Impaired Consent Capacity
Adults
Pregnant Women/Neonates/Fetal
Material
Prisoners
Non-English Speaking (translated
long or short form)
International Citizens
Normal Volunteers
Military Personnel and/or DoD
Civilian Employees
Patients
Appalachian Population
ADDITIONAL INFORMATION:
Please visit the IRB Survival Handbook for
more information on:
Children/Emancipated Minors
Students as Subjects
Prisoners
Impaired Consent Capacity Adults
Economically or Educationally
Disadvantaged Persons
Other Resources:
UKMC Residents or House Officers
[see requirement of GME]
Non-English Speaking [see also the
E-IRB Research Description section
on this same topic]
International Citizens [DoD SOP may
apply]
Military Personnel and/or DoD Civilian
Employees
8
0
0
Section 7 Page 2 of 3
47841


Traumatic brain injury or acquired brain
injury
Severe depressive disorders or Bipolar
disorders
Schizophrenia or other mental disorders
that
involve serious cognitive disturbances
Stroke
Developmental disabilities
Degenerative dementias
CNS cancers and other cancers with
possible CNS involvement
Late stage Parkinson’s Disease
Late stage persistent substance
dependence
Ischemic heart disease
HIV/AIDS
COPD
Renal insufficiency
Diabetes
Autoimmune or inflammatory disorders
Chronic non-malignant pain disorders
Drug effects
Other acute medical crises
Assessment of the potential recruitment of subjects with impaired consent capacity (or likelihood):
Check this box if your study does NOT involve direct intervention or direct interaction with subjects (e.g., record-review research, secondary
data analysis). If there is no direct intervention/interaction you will not need to answer the impaired consent capacity questions.
Does this study focus on adult subjects with any conditions that present a high likelihood of impaired consent capacity or fluctuations in
consent capacity? (see examples below)
Yes
No
If Yes and you are not filing for exemption certification, go to "Form T", complete the form, and attach it using the button below.
Examples of such conditions include:
Attachments
Section 7 Page 3 of 3
47841


Section 8 Page 1 of 6
47841


PREGNANT WOMEN/NEONATES/FETUSES
0 unresolved
comment(s)
For studies involving pregnant women, human fetuses and/or neonates, check the option that best fits your research, then address the questions and
requests for information. 
 Section 1: Research Involving Pregnant Women or Fetuses
Research Involving Pregnant Women or Fetuses
A. Explain why the proposed research is scientifically appropriate, including descriptions of any pre-clinical studies on pregnant
animals and any clinical studies on non-pregnant women that have been conducted and have provided data for assessing
potential risks to pregnant women and fetuses.
The etiology of preeclampsia is multi-factorial. Endothelial dysfunction and defective placental vascularization are key
features of the proposed underlying etiology in the pathogenesis of preeclampsia. In 1987, an endothelium
dependent relaxing factor, nitric oxide was identified as one of the important factors involved in maintaining underlying
vascular tone. In pathological states like preeclampsia, due to vascular endothelial dysfunction, decreased nitric oxide
production leads to vasoconstriction. Initial tests to determine endothelial dysfunction were invasive and were done in
non-pregnant women in the context of cardiovascular risk assessment. Celermajer and colleagues later developed a
non-invasive screening tool called flow mediated dilation (FMD) that measured nitric oxide dependent reactive
hyperemia in brachial artery after a 5-minute occlusion with a blood pressure cuff. This technique served as a surrogate
marker for coronary endothelial dysfunction. Cockell et al and Dorup et al applied the technique to the pregnant
population under the hypothesis that preeclampsia is associated with profound nitric oxide dependent vascular
endothelial dysfunction.
FMD is now a validated tool to assess vascular endothelium reactivity in pregnant women. The second biophysical
biomarker we are focusing on as part of our study is ultrasonographic Doppler assessment of the uterine artery at 3
different time points in pregnancy. This technique is also noninvasive and does not pose any maternal or fetal
risk. Measurement of flow mediated dilation in the forearm requires inflating the blood pressure cuff for 5 minutes which
might cause discomfort to the patient. This test has been extensively studied in pregnancy and is very useful in the
prediction of pre-eclampsia. The test is incorporated routinely in other countries (most notably England) as a screening
test for all women with low dose aspirin therapy given to those with evidence of poor placental vascular invasion. This is
not the standard of care for routine prenatal ultrasound assessment in United States but will be done for the purpose of
this study.
1. Tayyar A, Guerra L, Wright A, Wright D, Nicolaides KH. Uterine artery pulsatility index in the three trimesters of
pregnancy: effects of maternal characteristics and medical history. Ultrasound Obstet Gynecol 2015; 45: 689-97.
2. O'Gorman N, Tampakoudis G, Wright A, Wright D, Nicolaides KH. Uterine artery pulsatility index at 12, 22, 32 and 36
weeks' gestation in screening for pre-eclampsia. Ultrasound Obstet Gynecol 2016; 47: 565-72
The standard of care dose for preeclampsia prophylaxis is 81 mg per day. Roberge et al.(2018) showed aspirin
conferred a greater benefit in the reduction of preterm preeclampsia at a dose of = 100 mg when initiated < 16 weeks
of gestation. ASPRE trial showed a 60% reduction in the risk of preeclampsia when 150 mg of aspirin was used for
prophylaxis. 
Low dose aspirin is defined as dosages between 50 mg and 325 mg of aspirin. The dose of 162 mg, which we intend
to use in our study for preeclampsia prophylaxis, lies in the low dose range (Berger et al., 2008) and no maternal risks
have been identified.
B. Select the option that best describes the anticipated risk to the fetus:
Not greater than minimal; or
Greater than minimal risk and the risk to the fetus is caused solely by interventions or procedures that hold out the prospect
of direct benefit for the woman or the fetus.
C. Provide a rationale for anticipated risk:
Evidence for effectiveness of 162 mg vs. 81 mg of aspirin to reduce neonatal complications including intraventricular
hemorrhage (IVH): The rate of IVH, necrotizing enterocolitis (NEC), respiratory distress syndrome (RDS),
bronchopulmonary dysplasia (BPD), retinopathy of prematurity (ROP) and neonatal mortality are all dependent upon the
gestational age and delivery and a reduction in early preterm birth will reduce the frequency of these adverse events.
a. Meta-analysis has documented exposure to low dose aspirin reduced the rate of preterm birth in indicated population
(PARIS Collaboration trial)
b. Aspirin confers a greater benefit in the reduction of preterm preeclampsia at a dose of = 100 mg when initiated < 16
weeks of gestation (Roberge et al., 2018)
Low dose aspirin is defined as dosages between 50 mg and 325 mg of aspirin. The dose of 162 mg, which we intend
to use in our study for preeclampsia prophylaxis, lies in the low dose range (Berger et al., 2008). Systematic reviews of
randomized control trials of use of low dose aspirin in pregnancy have not demonstrated any maternal or fetal risks.
ASPRE trial showed no difference in the rates of intraventricular hemorrhage (IVH) when pregnant women identified as
high risk for preeclampsia received 150 mg of aspirin compared to those who received placebo (0.3% vs. 0.1%; OR
2.23, 95% CI: 0.09 -52.70). No significant differences were noted in other neonatal morbidities like anemia requiring
blood transfusion and necrotizing enterocolitis between the aspirin and the placebo groups. With altered
pharmacokinetics of aspirin in pregnancy, there is no physiological basis to believe a 12 mg increment in aspirin dose to
162 mg in our study poses a significantly increased risk for neonatal intraventricular hemorrhage.
In fact, a study currently underway at the University of Kentucky involves the use of Indomethacin, which is a stronger
NSAID than aspirin in the prophylaxis of neonatal IVH in preterm infants. Several trials with 162 mg of aspirin in
pregnancy for preeclampsia prophylaxis are currently registered in clinicaltrials.gov. Other institutions in United States
and other countries have approved this dose for testing given the safety findings above as no fetal risks have been
Section 8 Page 2 of 6
47841


identified.
D. Explain why any risk is the least possible for achieving the objectives of the research:
Other than the discomfort patient might experience at the time of inflating the blood pressure cuff to record the flow
mediated dilation of the brachial artery, use of low dose aspirin and ultrasound doppler assessments are not associated
with maternal and fetal risk. The interventions in our study are extensively validated in pregnant population with no risks
E. Select the options that apply:
 
Yes
No 1) This research holds out the prospect of direct benefit to the pregnant woman.
Yes
No 2) This research holds out the prospect of a direct benefit both to the pregnant woman and the fetus; or
Yes No
3) This research does not hold out the prospect of direct benefit for the woman or the fetus, but the risk to the fetus
is not greater than minimal and the purpose of the research is the development of important biomedical knowledge
that cannot be obtained by any other means.
If “Yes” to any of these three questions, informed consent must be obtained from the pregnant woman or her legally
authorized representative, but consent from the father is not required. The informed consent process should
include a clear explanation regarding the reasonably foreseeable impact of the research on the fetus.
Yes
No 4) This research holds out the prospect of a direct benefit solely to the fetus.
If “Yes”, informed consent must be obtained from the pregnant woman AND the father. The informed consent
process should include a clear explanation regarding the reasonably foreseeable impact of the research on the
fetus. NOTE: The father's informed consent need not be obtained if he is unable to consent because of
unavailability, incompetence, or temporary incapacity, or the pregnancy resulted from rape or incest.
 
Yes
No
5) This research will involve individuals under the age of 18 who are pregnant and are not considered
emancipated minors.
If ”Yes”, assent from the pregnant child and permission from her parent or legal guardian must be obtained.
Yes
No 6) Will there be any inducements, monetary or otherwise, offered to terminate a pregnancy?
Yes No
7) Will individuals performing research procedures have any part in any decisions as to the timing, method, or
procedures used to terminate a pregnancy?
Yes
No 8) Will individuals performing research procedures have any part in determining the viability of a fetus?
 Section 2. Research Involving Neonates
Research Involving Neonates
 A. Viable Neonates - A neonate, after delivery, that has been determined to be viable may be included in research only to the extent
permitted by and in accordance with the requirement of 45 CFR 46 Subpart A and Subpart D.
Yes
No Does your research involve viable neonates?
If yes, you will need to complete the Children subsection before submitting this application (if the Children subsection is not visible, go
to the "Subject Demographics" section, checkmark "Children", and save).
 B. Neonates of Uncertain Viability AND Nonviable Neonates - Until it has been ascertained whether or not a neonate is viable, a
neonate may not be involved in research covered by 45 CFR 46 Subpart B unless the IRB determines that certain conditions are met.
Your responses to the following will help the IRB determine whether the conditions are met.
Explain why the proposed research is scientifically appropriate and provide a description of any pre-clinical and clinical studies that have
been conducted which provide data for assessing potential risks to neonates. 
If not applicable, please enter "N/A".
Yes
No Will individuals engaged in the research have any part in determining the viability of a neonate?
 C. Neonates of Uncertain Viability - Additional Requirements - Select the option that applies to your research.
Section 8 Page 3 of 6
47841


Not Applicable
The research holds out the prospect of enhancing the probability of survival of the neonate to the point of viability, AND
any risk is the least possible for achieving that objective.
The research has the main purpose of the development of important biomedical knowledge, which cannot be obtained
by other means AND there will be no added risk to the neonate resulting from the research.
Explain the procedures that will be used to obtain legally effective informed consent of either parent of the neonate.
NOTE: If neither parent is able to consent because of unavailability, incompetence, or temporary incapacity, the legally
effective informed consent of either parent's legally authorized representative will be obtained. These procedures must
ensure that each individual providing informed consent will be fully informed regarding the reasonably
foreseeable impact of the research on the neonate. The father's informed consent need not be obtained if he is
unable to consent because of unavailability, incompetence, or temporary incapacity or the pregnancy resulted
from rape or incest.
 D. Nonviable Neonates – Additional Requirements - After delivery, a nonviable neonate may not be involved in research covered by 45
CFR 46 Subpart B unless the IRB determines that the following additional conditions are met.
Not Applicable
Yes
No 1) Will the vital functions of the neonate be artificially maintained?
If “Yes”, please explain:
Section 8 Page 4 of 6
47841


Yes
No 2) Does the research include procedures to terminate the heartbeat or respiration of the neonate?
Yes
No 3) Will there be any added risk to the neonate resulting from this research?
If “Yes”, please explain:
Yes No
4) Is the sole purpose of the research for the development of important biomedical knowledge that cannot be
obtained by other means?
If “Yes”, please explain:
5) Explain the procedures that will be used to obtain legally effective informed consent of both parents of the neonate.
Note: If either parent is unable to consent because of unavailability, incompetence, or temporary incapacity, the informed
consent of one parent of a nonviable neonate will suffice. The consent of the father need not be obtained if the pregnancy
resulted from rape or incest. The consent of a legally authorized representative of either or both of the parents of a
nonviable neonate will not suffice. These procedures must ensure that each individual providing informed consent
will be fully informed regarding the reasonably foreseeable impact of the research on the neonate.
 Section 3. Research Involving After Delivery, The Placenta, The Dead Fetus, Or Fetal Material
Research Involving After Delivery, The Placenta, The Dead Fetus, Or Fetal Material
A. This research proposes to use the following: (Check all that apply)
Placenta
The Dead Fetus
Macerated Fetal Material
Cells Excised from Dead Fetus
Tissue Excised from Dead Fetus
Organs Excised from Dead Fetus
Other
If 'Other' Describe:
NOTE: The use of any of the above must be conducted in accordance with any applicable Federal, State, or local laws,
regulations, and institutional policies regarding such activities.
B.
Yes
No Will any information associated with the material identified above be recorded for research purposes in such a
manner that living individuals can be identified, directly or through identifiers linked to those individuals?
If “Yes”, provide a rationale for the recording of identifiable information [Note: those individuals are considered to be
research subjects and all pertinent human subject regulations are applicable to their participation.]:
All identifiable information will be removed from the samples. All information will be de-identified and assigned unique
identification codes before storing the specimens. Only the bank staff will have access to the master list that links the
code to you. We will store the coded information in a secured computer behind locked doors. We will protect the
information with passwords/encryption. Encryption changes your information to another format to protect it from being
accessed by anyone outside of the approved staff
Section 8 Page 5 of 6
47841


Section 4. Research Not Otherwise Approvable Which Presents an Opportunity to Understand, Prevent, or Alleviate a Serious Problem
Affecting the Health or Welfare of Pregnant Women, Human Fetuses, or Neonates
If the study is Department of Health and Human Services (HHS) funded, or funding by HHS is sought, review by the Secretary of HHS and
posting in the Federal Register for public comments and review is required. If this category is applicable, the Office of Research Integrity will
prepare and submit a report of IRB review to the appropriate HHS institutional official.
Select all that apply:
Neonates
Pregnant Women
Fetal Material
Section 8 Page 6 of 6
47841


INFORMED CONSENT/ASSENT PROCESS/WAIVER
0 unresolved
comment(s)
For creating your informed consent attachment(s), please download the most up-to-date version listed in "All Templates" under the
APPLICATION LINKS menu on the left, and edit to match your research project.
Additional Resources:
Informed Consent/Assent Website
Waiver of Consent vs. Waiver of Signatures
Sample Repository/Registry/Bank Consent Template
Consent/Assent Tips:
If you have multiple consent documents, be sure to upload each individually (not all in a combined file).
If another site is serving as the IRB for the project, attach the form as a “Reliance Consent Form” so the document will not receive
a UK IRB approval stamp; the reviewing IRB will need to stamp the consent forms.
Changes to consent documents (e.g., informed consent form, assent form, cover letter, etc...) should be reflected in a 'tracked
changes' version and uploaded separately with the Document Type "Highlighted Changes".
It is very important that only the documents you wish to have approved by the IRB are attached; DELETE OUTDATED FILES --
previously approved versions will still be available in Protocol History.
Attachments that are assigned a Document Type to which an IRB approval stamp applies will be considered the version(s) to be
used for enrolling subjects once IRB approval has been issued. 
Document Types that do NOT get an IRB approval stamp are:
"Highlighted Changes",
"Phone Script", and
"Reliance Consent Form",
"Sponsor's Sample Consent Form".
How to Get the Section Check Mark
1. You must:
a) provide a response in the text box below describing how investigators will obtain consent/assent, and 
b) check the box for at least one of the consent items and/or check mark one of the waivers
2. If applicable attach each corresponding document(s) as a read-only PDF.
3. If you no longer need a consent document approved (e.g., closed to enrollment), or, the consent document submitted does not
need a stamp for enrolling subjects (e.g., umbrella study, or sub-study), only select "Stamped Consent Doc(s) Not Needed".
4. After making your selection(s) be sure to scroll to the bottom of this section and SAVE your work!
Check All That Apply
Informed Consent Form (and/or Parental Permission Form and/or translated short form)
Assent Form
Cover Letter (for survey/questionnaire research)
Phone Script
Informed Consent/HIPAA Combined Form
Debriefing and/or Permission to Use Data Form
Reliance Consent Form
Sponsor's sample consent form for Dept. of Health and Human Services (DHHS)-approved protocol
Stamped Consent Doc(s) Not Needed
Attachments
Informed Consent Process:
Using active voice, in the text box below, describe how investigators will obtain consent/assent. Include:
the circumstances under which consent will be sought and obtained
the timing of the consent process (including any waiting period between providing information and obtaining consent)
Section 9 Page 1 of 4
47841


who will seek consent
how you will minimize the possibility of coercion or undue influence
the method used for documenting consent
if applicable, who is authorized to provide permission or consent on behalf of the subject
if applicable, specific instruments or techniques to assess and confirm potential subjects’ understanding of the information
Will electronic consent form/process be utilized on-site or remotely for this study?
Yes
No
If yes, in addition to addressing the above bullet points, describe the e-consent method and platform, including any hyperlinks, videos,
or enhancements used to convey information, if applicable. Attach a representation of the e-consent with signature fields. For
guidance, see the ORI E-Consent web page.
Note: all individuals authorized to obtain informed consent should be designated as such in the E-IRB "Study Personnel" section of
this application.
Special considerations may include:
Obtaining consent/assent for special populations such as children, prisoners, or people with impaired decisional capacity
Research Involving Emancipated Individuals 
If you plan to enroll some or all prospective subjects as emancipated, consult with UK legal counsel prior to submitting this
application to the IRB. Include research legal counsel’s recommendations in the "Additional Information" section as a separate
document.
Research Involving Non-English Speaking Subjects 
For information on inclusion of non-English speaking subjects, or subjects from a foreign culture, see IRB Application Instructions
for Recruiting Non-English Speaking Participants or Participants from a Foreign Culture.
Research Repositories 
If the purpose of this submission is to establish a research repository describe the informed consent process. For guidance
regarding consent issues, process approaches, and sample language see the Sample Repository/Registry/Bank Consent
Template.
After identifying eligible patients for this study, the risks and benefits of the study will be discussed with the participant prior to
obtaining consent. Certified Spanish translators identified as study personnel will be available onsite for recruiting and consenting
Hispanic patients. Potential participants will be notified of their right to decline study participation without any consequences to the
standard healthcare they will otherwise receive. Women will be recruited into the study and will be provided with a written, informed
consent prior to 16 weeks of gestation. For Hispanic patients, Spanish consent form will be made available. Only the study personnel
will be obtaining consent A research repository with the blood, urine and cord blood specimens will be created to store the samples
for a period of 2 years after the current study ends. Patients will be notified of this at the time of their consenting process.
The person in charge of the study is Dr. John O’Brien of the University of Kentucky, Department of Maternal Fetal Medicine. If the
subjects have questions, suggestions, or concerns regarding this study his contact information is: Dr. John O’Brien at 859-218-0765
If subjects have any questions, suggestions or concerns about their rights as a volunteer in this research, the research staff can be
contacted at the University of Kentucky (UK) Office of Research Integrity (ORI) between the business hours of 8am and 5pm EST,
Monday-Friday at 859-257-9428 or toll free at 1-866-400-9428
Request for Waiver of Informed Consent Process
If you are requesting IRB approval to waive the requirement for the informed consent process, or to alter some or all of the
elements of informed consent, complete, Section 1 and Section 2 below.
Note: The IRB does not approve waiver or alteration of the consent process for greater than minimal risk research, except
for planned emergency/acute care research as provided under FDA regulations. Contact ORI for regulations that apply to
single emergency use waiver or acute care research waiver (859-257-9428).
SECTION 1.
Check the appropriate item:
I am requesting a waiver of the requirement for the informed consent process.
I am requesting an alteration of the informed consent process.
If you checked the box for this item, describe which elements of consent will be altered and/or omitted, and justify the
alteration.
SECTION 2.
Explain how each condition applies to your research.
a) The research involves no more than minimal risk to the subject.
b) The rights and welfare of subjects will not be adversely affected.
c) The research could not practicably be carried out without the requested waiver or alteration.
Section 9 Page 2 of 4
47841


d) Whenever possible, the subjects or legally authorized representatives will be provided with additional pertinent information
after they have participated in the study.
Section 9 Page 3 of 4
47841


Request for Waiver of Signatures
If you are requesting IRB approval to waive the requirement for signatures on informed consent forms, your research
activities must fit into one of three regulatory options:
1. The only record linking the participant and the research would be the consent document, and the principal risk would be
potential harm resulting from a breach of confidentiality (e.g., a study that involves participants who use illegal drugs).
2. The research presents no more than minimal risk to the participant and involves no procedures for which written consent
is normally required outside of the research context (e.g., a cover letter on a survey, or a phone script).
3. The participant (or legally authorized representative) is a member of a distinct cultural group or community in which
signing forms is not the norm, the research presents no more than minimal risk to the subject, and there is an appropriate
alternative mechanism for documenting that informed consent was obtained.
Select the option below that best fits your study. 
If the IRB approves a waiver of signatures, participants must still be provided oral or written information about the study.
To ensure you include required elements in your consent document, use the Cover Letter Template as a guide. There is
an English and a Spanish version.
 
Option 1
Describe how your study meets these criteria:
a) The only record linking the participant and the research would be the consent document:
b) The principal risk would be potential harm resulting from a breach of confidentiality (i.e., a study that involves subjects
who use illegal drugs).
Under this option, each participant (or legally authorized representative) must be asked whether (s)he wants to sign a
consent document; if the participant agrees to sign a consent document, only an IRB approved version should be
used.
Option 2
Describe how your study meets these criteria:
a) The research presents no more than minimal risk to the participant:
b) Involves no procedures for which written consent is normally required outside of the research context (i.e. a cover
letter on a survey, or a phone script):
Option 3
Describe how your study meets these criteria:
a) The subject (or legally authorized representative) is a member of a distinct cultural group or community in which
signing forms is not the norm.
b) The research presents no more than minimal risk to the subject.
c) There is an appropriate alternative mechanism for documenting that informed consent was obtained.
Section 9 Page 4 of 4
47841


STUDY PERSONNEL
0 unresolved comment(s)
Do you have study personnel who will be assisting with the research?
After selecting 'Yes' or 'No' you must click the 'Save Study Personnel Information' button. 
Yes
No
Manage Study Personnel
Identify other study personnel assisting in research project:
The individual listed as PI in the 'PI Contact Information' section should NOT be added to this section.
If the research is required for a University of Kentucky academic program, the faculty advisor is also considered study personnel and should be listed below. ***Residents and
students who are PI’s are encouraged to designate the faculty advisor or at least one other individual as a contact with an editor role (DP).***
Role: DP = Editor (individual can view, navigate, and edit the application for any review phase (IR, CR/FR, MR) or 'Other Review", and submit Other Reviews on behalf of the
PI.)
Role: SP = Reader (individual can view and navigate through the currently approved application only.)
To add an individual via the below feature:
Search for personnel;
Click "select" by the listing for the person you want to add;
For each person, specify responsibility in the project, whether authorized to obtain informed consent, AND denote who should receive E-IRB notifications (contact status).
NOTE: Study personnel must complete human subject protection (HSP) and Responsible Conduct of Research (RCR) training before implementing any research
procedures. For information about training requirements for study personnel, visit UK’s HSP FAQ page, the RCR Getting Started page, or contact ORI at 859-257-
9428. If you have documentation of current HSP training other than that acquired through UK CITI, you may submit it to ORI (HSPTrainingSupport@uky.edu) for
credit.
Study personnel assisting in research project: 
Last Name
First
Name
Responsibility In
Project
Role
A
C
Contact
Degree
StatusFlag
(HSP)
(HSP)Date
(RCR)
Removed?
Last
Updated
SFI
Active
Cockerham-
Morris
Cynthia
Study Coordinator
DP
Y
Y
BSN
P
Y
04/09/2025
Y
N
09/14/2022
N
Y
Hawk
Gregory
Data
Analysis/Processing
SP
N
N
 
P
Y
03/01/2023
Y
N
04/28/2025
N
Y
Shrestha
Asmita
Project
Assistance/Support
DP
N
Y
MPH
P
Y
10/10/2022
Y
N
07/06/2022
N
Y
Stanton
Victoria
Data
Analysis/Processing
SP
N
N
 
P
Y
08/12/2024
Y
N
04/28/2025
N
Y
Thompson
Katherine
Data
Analysis/Processing
SP
N
N
 
P
Y
11/08/2024
Y
N
04/28/2025
N
Y
Whitley
Wendy
Study Coordinator
DP
Y
Y
BSN
P
Y
11/06/2023
Y
N
02/02/2021
N
Y
Armstrong
Alexandra
Project
Assistance/Support
DP
Y
N
BSN
P
Y
12/27/2023
N
Y
05/20/2024
N
N
Bauer
John
Faculty Advisor
SP
Y
N
PhD
P
Y
07/30/2023
Y
Y
03/14/2025
N
Y
Bidros
Patrick
Project
Assistance/Support
SP
N
N
 
P
Y
08/30/2023
Y
Y
09/22/2021
N
Y
Boerrigter
Ashley
Project
Assistance/Support
DP
Y
N
MD
P
Y
07/21/2022
Y
Y
03/14/2025
N
Y
Butler
Sara
Data Collection
SP
N
N
 
P
N
03/13/2021
 
Y
09/14/2022
N
N
Chavan
Niraj
Faculty Advisor
DP
Y
N
MD,
MPH
S
N
03/03/2021
 
Y
09/22/2021
N
N
Critchfield
Agatha
Recruitment
SP
Y
N
 
P
N
04/20/2017
 
Y
12/02/2019
N
N
D'Alessandri
Brianna
Project
Assistance/Support
SP
Y
N
MSN
P
N
04/11/2022
N
Y
05/20/2024
N
Y
Hammond
Tyler
Sub-Investigator
SP
Y
N
MS
N
04/05/2022
N
Y
03/14/2025
N
N
Hansen
Wendy
Recruitment
SP
Y
N
MD
P
Y
01/17/2023
Y
Y
05/20/2024
N
Y
Hendrix
Nancy
Recruitment
SP
Y
N
 
P
Y
11/14/2024
Y
Y
05/20/2024
N
Y
Huang
Hong
Data
Analysis/Processing
SP
N
N
 
P
Y
07/28/2022
Y
Y
03/14/2025
N
Y
Joseph
Rahul
Project
Assistance/Support
SP
N
N
MD
P
Y
02/07/2023
Y
Y
03/14/2025
N
Y
Lewis
Regina
Project
Assistance/Support
DP
Y
N
MS
P
Y
03/06/2023
Y
Y
05/20/2024
N
Y
MacLeod
Erin
Project
Assistance/Support
SP
Y
N
MD
P
N
12/28/2020
 
Y
09/14/2022
N
Y
McKinley
Brittany
Data Collection
SP
Y
N
MD
S
N
11/02/2020
 
Y
09/22/2021
N
N
McKinney-
Whitlock
Alisa
Project
Assistance/Support
SP
N
N
CCRP
P
Y
12/10/2024
Y
Y
03/14/2025
N
Y
Mirsky
Elizabeth
Project
Assistance/Support
SP
Y
N
MD
P
Y
07/09/2023
Y
Y
03/14/2025
N
Y
Section 10 Page 1 of 2
47841


Last Name
First
Name
Responsibility In
Project
Role
A
C
Contact
Degree
StatusFlag
(HSP)
(HSP)Date
(RCR)
Removed?
Last
Updated
SFI
Active
Patel
Neil
Project
Assistance/Support
SP
Y
N
MD
P
N
07/15/2021
N
Y
05/20/2024
N
N
Playforth
Karen
Recruitment
SP
Y
N
 
P
Y
06/28/2022
N
Y
03/08/2022
N
Y
Schanbacher
Avery
Project
Assistance/Support
SP
N
N
 
P
N
07/08/2019
 
Y
09/14/2022
N
Y
Schanbacher
Brandon
Data
Analysis/Processing
SP
N
N
MS
P
Y
10/09/2023
Y
Y
03/14/2025
N
Y
Sepulveda
Norma
Project
Assistance/Support
SP
Y
N
 
P
N
01/01/2019
 
Y
10/27/2020
N
N
Sharma
Deepti
Data Collection
SP
Y
N
 
P
N
01/25/2021
 
Y
10/27/2020
N
N
Shoemaker
Robin
Faculty Advisor
SP
N
N
PhD
P
Y
12/30/2022
Y
Y
03/14/2025
N
Y
Srinivasan
Aarthi
Co-Investigator
SP
Y
N
MD,
MS
P
N
09/21/2019
 
Y
09/14/2022
N
N
Stanley
Zachary
Project
Assistance/Support
SP
Y
N
MD
S
N
04/16/2020
 
Y
09/14/2022
N
N
Su
Leon
Project
Assistance/Support
SP
N
N
 
S
Y
11/13/2023
N
Y
09/14/2022
N
N
Vignes
Katherine
Co-Investigator
DP
Y
Y
MD
P
N
02/02/2020
 
Y
07/10/2023
N
N
Ward
Calvin
Project
Assistance/Support
SP
Y
N
MD
P
N
04/28/2021
 
Y
07/10/2023
N
N
Section 10 Page 2 of 2
47841


RESEARCH DESCRIPTION
0 unresolved
comment(s)
You may attach a sponsor’s protocol pages in the “Additional Information” section and refer to them where necessary in
the Research Description. However, each prompt that applies to your study should contain at least a summary paragraph.
Pro Tips:
Save your work often to avoid losing data.
Use one of the attachment buttons in this section or under the Additional Information section to include supplemental
information with your application. During the document upload process, you will be able to provide a brief description
of the attachment.
Background
Include a brief review of existing literature in the area of your research. You should identify gaps in knowledge that should be addressed
and explain how your research will address those gaps or contribute to existing knowledge in this area. For interventional research,
search PubMed and ClinicalTrials.gov for duplicative ongoing and completed trials with same condition and intervention(s).
Preeclampsia is a part of the spectrum of hypertensive disorders of pregnancy and is the leading cause of significant maternal and
fetal morbidity and mortality. The incidence ranges from 3% to 8% of all pregnancies. The pathophysiology can involve multiple organ
systems and the etiology is multi-factorial. Defective placental implantation, endothelial dysfunction, defective placental angiogenesis,
platelet activation, oxidative stress and autoimmunity are some aberrant physiologies that contribute to preeclampsia. The potential
role of endothelial dysfunction in the pathogenesis of disease was initially described in the pathogenesis of atherosclerosis and as a
risk marker for cardiovascular events in non-pregnant adults. Ludmer et al demonstrated a paradoxical vasoconstriction with
intracoronary infusion of acetyl choline in coronary atherosclerosis. This sentinel study led to an appreciation of a possible defect in
endothelial vasodilation in human atherosclerosis. Furchgott and Zawadski demonstrated the vascular endometrium released a
substance named endothelial-derived relaxing factor (EDRF) which had the ability to influence the action of the underlying smooth
muscle in the vascular wall. This substance was later identified as nitric oxide (NO). The existence of a nitric oxide dependent pathway,
L-arginine-NO-CGMP pathway in pregnancy has been demonstrated in animal models (Weiner et al.). Yallampalli et al. examined the
human endometrium at various gestational ages and demonstrated that the L-arginine-NO-cGMP pathway helped regulate myometrial
contractility throughout gestation. Normal pregnancy is associated with profound cardiovascular changes with increase in cardiac
output and heart rate and decrease in peripheral vascular resistance and mean arterial blood pressure. While endothelium-derived
prostacyclin has shown to have a role, nitric oxide has been identified as an important regulator of blood pressure in pregnancy. Molnar
and Hertelendy used animal models to show prolonged blockade of nitric oxide synthase inhibitor leads to a preeclampsia like state
with sustained hypertension, thrombocytopenia, a reduced intravascular compartment, fetal growth retardation and potentially fetal
demise. Additional evidence of endothelial dysfunction in preeclampsia in humans was provided by Mccarthy et al. Small arteries from
the subcutaneous fat were examined at the time of cesarean section in normal pregnant women and women with preeclampsia. The
authors showed acetylcholine(endothelial) mediated relaxation of the arteries was impaired in women with preeclampsia compared to
normotensive pregnant women providing evidence of endothelial dysfunction in preeclampsia.
Many invasive and non-invasive techniques were developed as surrogate markers for coronary endothelial function. Such tests were
later expanded to assess both macrovascular and microvascular endothelial function. Celermajer and colleagues 
demonstrated that the reactive hyperemia produced in the brachial artery after an occlusion with a blood pressure cuff was endothelial,
NO dependent and was termed as Flow mediated dilation (FMD). FMD was originally developed to assess coronary artery endothelial
function. Preeclampsia is a condition associated with profound dysfunction of NO dependent vascular endothelium relaxation. Several
studies have validated the use of flow mediation dilation of brachial artery to evaluate maternal vascular endothelial function in women
with preeclampsia. Increased blood pressure and increased peripheral vascular resistance is partly due to decreased NO production
by a dysfunctional vascular endothelium resulting in decreased FMD. 
Defective placental trophoblast invasion is associated with incomplete spiral arterial remodeling. Ultrasound assessment of the uterine
arteries can provide an objective evidence of this underlying dysfunction. Role of Doppler ultrasound in the comprehensive risk
assessment for preeclampsia has been extensively described in the literature. In 2018, the International Society for Ultrasound in
Obstetrics and Gynecology (ISUOG) described practice guidelines on the use of ultrasound in the screening and follow-up tool for
preeclampsia. Pulsatility index (PI), Resistance index (RI) and Systolic/Diastolic (S/D) ratio) are the doppler indices available to
interrogate the impedance to the flow in the uterine artery. Of these, mean PI is the most predictive index and is the preferred
methodology in the screening for preeclampsia. This measure incorporates the variability of blood velocity in a cardiac cycle rather
than just a two-point measurement as in RI. Bilateral uterine artery notching in the second trimester has a similar sensitivity as PI and
the combination can be used as an effective ultrasound screening tool for preeclampsia.
The anti-platelet action, and altered thromboxane/prostacyclin ratio relate to low dose aspirin therapy have been extensively explored
for the prevention of preeclampsia. One of the proposed theories for development of preeclampsia is that defective placental invasion
and spiral arterial remodeling leads to activation of platelets and the coagulation cascade. The hypothesis is that aspirin can prevent or
delay the onset of platelet aggregation. The role of aspirin in the prevention of preeclampsia was first investigated by Crandon et al.
The incidence of preeclampsia was significantly lower in patients who frequently took aspirin or aspirin related products in pregnancy.
Since then several studies have evaluated the efficacy of low dose aspirin prophylaxis in the prevention of preeclampsia in doses
ranging from 50 mg to 150 mg. In 2014, a United States Preventive Services Task Force (USPSTF) guidelines supported the use of
low dose aspirin based on a meta-analysis that showed a 2-5% absolute risk reduction for preeclampsia. USPSTF defines high and
Section 11 Page 1 of 10
47841


moderate risk factors for preeclampsia. The American College of Obstetrics and Gynecology (ACOG) and the Society of Maternal
Fetal Medicine (SMFM) endorse the USPSTF recommendations. Low dose aspirin is supported for women who have one or more of
the high-risk factors or multiple moderate risk factors for preeclampsia. This prophylaxis is prescribed initially between 12 and 28
weeks of gestation (optimally before 16 weeks). In support of the USPSTF recommendations, a meta-analysis in 2017 showed a
significant reduction in the incidence of preeclampsia when aspirin was initiated =16 weeks and at a dose of 100 mg. Furthermore, in
2017, the ASPRE trial, a large multi-center, double-blind, placebo controlled trial was published demonstrating women who were
stratified as high risk for preeclampsia by means of first trimester screening including uterine artery Doppler assessment, and who
received a daily dose of 150 mg of aspirin, had a 60% reduction in the incidence of preterm preeclampsia (< 37 weeks of gestation) . 
Despite this abundance of evidence on the beneficial role of aspirin to prevent preeclampsia, relatively few mechanistic studies have
been performed to understand better how aspirin modifies the pathogenesis of the disease. Hashemi et al showed a significant
increase in FMD in preeclamptic women who were placed on low dose aspirin which was observed throughout pregnancy and
persisted until 2 months postpartum. These findings suggest aspirin’s ability to decrease endothelial dysfunction by selective inhibition
of thromboxane A2 may impact the peripheral vasculature in pregnancy. There is also sparce data on how aspirin modifies the
impedance to flow centrally in the uterine arteries when impaired placental implantation is observed. One study identified a non-
significant trend towards reduced placental resistance in women treated with aspirin by assessing uterine arterial Doppler indices at
32-34 weeks of gestation. However, other evidence suggests aspirin may not alter abnormal uterine artery flow even when initiated
early on in the gestation.
The therapeutic benefits or the toxicological effects of drugs during pregnancy is best studied with a two compartment (maternal –
fetal) unit. This is a simple kinetic model that can used to study the rate, distribution and duration of drug exposure in the mother and
the fetus. The volume of distribution has been noted to be increased when the 2 compartment model has been studied. The
pharmacokinetics of a drug is also influenced by the metabolism in a third compartment, placental compartment and the by the kinetics
of the drug metabolite itself. 
Szeto, H.H. Pharmacokinetics in the ovine maternal-fetal unit. Annu Rev Pharmacol Toxicol 2:221-243, 1982
In a non-pregnant state, following ingestion of 162 mg of aspirin, the mean maximum plasma concentrations of acetyl salicylic acid and
salicylic acid was 1.8 ± 0ꞏ6 mg mg /L and 7.6 ± 1ꞏ4 mg/L respectively. The lowest measured plasma concentration of salicylic acid to
fully inhibit arachidonic acid induced platelet aggregation was 5.7 mg/L seen when 162 mg of aspirin was used per day.
Hobl, E. L., Schmid, R. W., Stimpfl, T., Ebner, J., & Jilma, B. (2015). Absorption kinetics of low-dose chewable aspirin–implications for
acute coronary syndromes. European journal of clinical investigation, 45(1), 13-17.
Aspirin pharmacokinetics have been studied in pregnancy. The metabolism of aspirin is altered in pregnancy due to physiological
changes in gastrointestinal absorption, accumulation in body fat and decreased drug binding to plasma proteins and changes in renal
excretion due to increase renal plasma flow and glomerular filtration rate. Jacobson and colleagues investigated the transfer of
acetylsalicylic acid in a perfused human placental cotyledon and its effects on fetal placental unit. When isolated perfused human
cotyledons were treated with acetyl salicylic acid, 60% of acetyl salicylic acid was extracted from the maternal perfusate when steady
state was reached and less than 15% was noted in the fetal circulation. These levels were much lower than those known to inhibit
thromboxane or alter fetal perfusion pressure. The much lower concentrations seen in the fetal circulation than what is extracted from
the maternal perfusate might be presumably due to placental metabolism
Jacobson, R. L., Brewer, A., Eis, A., Siddiqi, T. A., & Myatt, L. (1991). Transfer of aspirin across the perfused human placental
cotyledon. American Journal of Obstetrics & Gynecology, 165(4), 939-944.
Although this intervention is well supported and low risk, aspirin has several pharmacokinetic mechanisms of action and the way it
modifies disease in some pregnant patients is unclear5. Aspirin triggered lipoxins (ATL/LXA4) are lipid mediators produced from
arachidonic acid that are thought to work through anti-oxidant and anti-inflammatory roles to result in tissue specific, and possibly,
systemic change. These mediators occur naturally but are increased by aspirin administration and pregnant mouse models show
reduction of pre-eclamptic disease with administration6. Further, a cohort study of pregnant women showed lower circulating levels of
ATL/LXA4 and placental receptor (ALX) expression in pre-eclamptic women7. As pre-eclampsia is a disease of widespread
endothelial damage and inflammation triggered by placental dysfunction, we surmise that aspirin’s effectiveness as a prophylactic
therapy could be through alteration of ATL/LXA4 and receptor (ALX) expression at the placental level. 
The pharmacokinetics of aspirin in pregnancy has not been clearly defined and existing sparce data from animal and some human
placental models therefore supports the construct that the efficacy of the intervention may be dependent upon dose and volume of
distribution.
Objectives
List your research objectives. Please include a summary of intended research objectives in the box below.
The objective of our study is to determine if low dose aspirin has a dose dependent response to modify maternal endothelial
dysfunction and impedance in uterine arteries when used in the prophylaxis of preeclampsia prevention in women identified as at high
risk for development of preeclampsia.
Another objective of our current study is to understand the important mechanism of prevention of pre-eclampsia with the ultimate goal
to improve targeting of therapy to pregnant women who will benefit from aspirin exposure in pregnancy. We will accomplish this by
evaluating ATL/LXA4 concentrations as a mechanism of aspirin benefit.
Study Design
Section 11 Page 2 of 10
47841


Describe and explain the study design (e.g., observational, secondary analysis, single/double blind, parallel, crossover, deception, etc.).
Clinical Research: Indicate whether subjects will be randomized and whether subjects will receive any placebo.
Community-Based Participatory Research: If you are conducting community-based participatory research (CBPR), describe
strategies for involvement of community members in the design and implementation of the study, and dissemination of results from
the study.
Qualitative research: Indicate ranges where flexibility is needed, if a fixed interview transcript is not available, describe interview
topics including the most sensitive potential questions.
Research Repositories: If the purpose of this submission is to establish a Research Repository (bank, registry) and the material
you plan to collect is already available from a commercial supplier, clinical lab, or established IRB approved research repository,
provide scientific justification for establishing an additional repository collecting duplicate material. Describe the repository design
and operating procedures. For relevant information to include, see the UK Research Biospecimen Bank Guidance or the UK
Research Registry Guidance.
This is a single center, prospective, randomized, open-label clinical trial. The experimental group will include pregnant women who are
identified at high risk for preeclampsia either by history, presence of risk factors, or abnormal uterine artery Doppler impedance. They
will be divided into two groups based on their body mass index (BMI) (<30 and =30). Patients in each group will be randomized to
receive either aspirin 81 mg (1 tablet of baby aspirin) or aspirin 162 mg (2 tablets of baby aspirin) daily initiated between 11 and 16
weeks of gestation and continued until 36 weeks of gestation. There will be a third control group of pregnant women at low risk for
preeclampsia based on their risk factor assessment to provide baseline data. The control group will not receive aspirin. Both of the
experimental and control groups will be assessed with uterine artery Doppler studies and FMD of the brachial artery at three different
time points in pregnancy: at enrollment between 11 and 16 weeks, between 18 and 22 weeks (+/- 7 days), and between 28 and 32
weeks of gestation(+/- 7 days). We will obtain baseline blood and urine samples at the time of enrollment and later between 28 and 32
weeks (+/- 7 days) to assess salicylate levels, thromboxane and endothelin-1 levels. We will also obtain cord blood and placental
samples from the experimental and control population at the time of delivery.
Attachments
Subject Recruitment Methods & Advertising
Describe how the study team will identify and recruit subjects. Please consider the following items and provide additional information as
needed so that the IRB can follow each step of the recruitment process.
How will the study team identify potential participants?
Who will first contact the potential subjects, and how?
Will you use advertisements? If so, how will you distribute those?
How and where will the research team meet with potential participants?
If applicable, describe proposed outreach programs for recruiting women, minorities, or disparate populations.
How you will minimize undue influence in recruitment?
Attach copies of all recruiting and advertising materials (emails, verbal scripts, flyers, posts, messages, etc.).
For additional information on recruiting and advertising:
IRB Application Instructions - Advertisements
PI Guide to Identification and Recruitment of Human Subjects for Research
Participants will be recruited from UK Polk Dalton clinic, Good Samaritan Obstetrics and Gynecology clinic, and the Good Samaritan
Ultrasound unit. Patients will be greeted in person and recruitment will be done in a private room. Study personnel who work in the
clinics listed above with access to patients' identity and information will be involved in patient recruitment and consenting processes.
Recruitment of Hispanic patients will be accomplished by certified Spanish translators identified as support staff under study
personnel who will be present onsite. The initial recruitment process will not involve any Hispanic patients until a modification is
submitted to the IRB with a detailed Spanish consent. The recruitment of the Hispanic patients will begin after the consent form in
Spanish has been approved by the IRB.
There will be no advertising.
Attachments
Section 11 Page 3 of 10
47841


Back to Top
Research Procedures
Describe how the research will be conducted.
What experience will study participants have?
What will study participants be expected to do?
How long will the study last?
Outline the schedule and timing of study procedures.
Provide visit-by-visit listing of all procedures that will take place.
Identify all procedures that will be carried out with each group of participants.
Describe deception and debrief procedures if deception is involved.
Differentiate between procedures that involve standard/routine clinical care and those that will be performed specifically for this
research project. List medications that are explicitly forbidden or permitted during study participation.
The research procedures including patient enrollment will happen at the time of their routine prenatal visits and no additional visits for
the purpose of this research are anticipated. The procedures patients will undergo during their visits and the timeline are shown in the
attached table. The experimental group will include pregnant women who are identified at high risk for preeclampsia either by history,
presence of risk factors, or abnormal uterine artery Doppler impedance. They will be divided into two groups based on their body
mass index (BMI) (<30 and >=30). Patients in each group will be randomized to receive either aspirin 81 mg (1 tablet of baby aspirin)
or aspirin 162 mg (2 tablets of baby aspirin) daily initiated between 11 and 16 weeks of gestation and continued until 36 weeks of
gestation. There will be a third control group of pregnant women at low risk for preeclampsia based on their risk factor assessment to
provide baseline data. The control group will not receive any aspirin.
After their initial enrollment, patients in the experimental group will be divided into 2 groups based on their body mass index (BMI) : <30
and >=30. Patients in each group will be randomized to receive aspirin 81 mg(1 low-dose aspirin tablet) or aspirin 162 mg (2 low dose
aspirin tablets per day) daily until 36 weeks of gestation. Prescribing low dose aspirin is part of the standard prenatal care for women
who are identified as at high risk for preeclampsia.
The prescription for aspirin for the patients enrolled in the study will be sent to the UK Good Samaritan Hospital outpatient pharmacy.
When patients are randomized to Aspirin 162 mg ( 2 tablets of baby aspirin) and there is an additional cost to the patient due to the
higher dose. The Division of Maternal Fetal Medicine at UK will receive a monthly statement from UK Good Samaritan Hospital
pharmacy for every dose of 162mg that was filled during the previous month. 
Patients in both the experimental and control groups will undergo two sets of ultrasound assessments - uterine and brachial arteries,
during their routine prenatal ultrasound evaluation at different time points in their pregnancy at UK Good Samaritan hospital. Initial
assessment would be during their initial enrollment less than 16 weeks of gestation. The other two would be between 20 and 22 weeks
(+/- 7 days) and between 28 and 32 (+/- 7 days) weeks during their routine ultrasound evaluation for fetal anatomy and fetal growth
respectively. During their ultrasound visit, after completion of their routine evaluation indicated for that visit, doppler assessment of the
uterine arteries will be done. Following this, Doppler assessment of the brachial artery will be performed known as the flow mediated
dilation (FMD). 
The baseline diameter of the brachial artery will be first recorded using the ultrasound transducer probe. Thereafter a blood pressure
cuff will be placed around the forearm distal to the ultrasound probe and inflated to 25-50 mm Hg above the systolic arterial pressure
for 5 minutes to elicit a reactive hyperemic stimulus. The cuff will then be deflated and the longitudinal image of the brachial artery will
be obtained continuously from 30 seconds before and 2 minutes after the cuff deflation. Flow mediated dilation will be calculated
using the following equation: FMD (%) = (Peak diameter - Baseline diameter) / Baseline diameter
Patients will also provide an extra tube of blood and urine specimen collected during their routine prenatal laboratory evaluation
performed at the time of first trimester screening and for gestational diabetes screening in the late second/early third trimester. Finally,
cord blood and will be collected in 15 patients from each group to assess whether the variation in dose results in appreciably greater
fetal cord blood concentrations. The first 15 deliveries from each group in the study will be selected for cord blood and placental
collection at the time of delivery. Medical records will be abstracted to collect demographic information, medical and prenatal history,
treatment course, ultrasound information, information related to delivery and neonate after birth (Birth weight, gender, APGARS and
neonatal complications).
The urine, maternal blood, cord blood and placental samples collected during the study will be stored in a locked freezer behind
locked doors in Dr. John Bauer's laboratory at the Medical Science building #472. All identifiable information will be removed from the
samples. All information will be de-identified and assigned unique identification codes before storing the specimens. Only the bank
staff will have access to the master list that links the code to you. We will store the coded information in a secured computer behind
locked doors. We will protect the information with passwords/encryption. Encryption changes your information to another format to
protect it from being accessed by anyone outside of the approved staff.
Attachments
Attach Type
File Name
ResearchProcedures
Research procedures timeline pdf.pdf
Data Collection & Research Materials
Section 11 Page 4 of 10
47841


In this section, please provide the following:
Describe all sources or methods for obtaining research materials about or from living individuals (such as specimens, records,
surveys, interviews, participant observation, etc.), and explain why this information is needed to conduct the study.
For each source or method described, please list or attach all data to be collected (such as genetic information, interview scripts,
survey tools, data collection forms for existing data, etc.).
If you will conduct a record or chart review, list the beginning and end dates of the records you will view.
Please find the data collection sheet attached
Attachments
Attach Type
File Name
DataCollection
Data Collection highlighted copy.docx
DataCollection
Data Collection clean copy.docx
Resources
Describe the availability of the resources and adequacy of the facilities that you will use to perform the research. Such resources may
include:
Staffing and personnel, in terms of availability, number, expertise, and experience;
Computer or other technological resources, mobile or otherwise, required or created during the conduct of the research;
Psychological, social, or medical services, including equipment needed to protect subjects, medical monitoring, ancillary care, or
counseling or social support services that may be required because of research participation;
Resources for communication with subjects, such as language translation/interpretation services.
The facilities that will be used for the study will be UK Chandler hospital, UK Polk Dalton clinic, UK Good Samaritan hospital, UK Good
Samaritan ultrasound unit, UK Good Samaritan Radiology unit and UK laboratories. The blood and urine samples will be de-identified
and stored in Dr. John Bauer's lab at the University of Kentucky. The participants will continue to receive prenatal care as per her their
standard prenatal care from their obstetricians. If any medical concerns are addressed they will be immediately be referred back to
their obstetrician.
Potential Risks & Benefits
Risks
Describe any potential risks – including physical, psychological, social, legal, ability to re-identify subjects, or other risks. Assess
the seriousness and likelihood of each risk.
Which risks may affect a subject’s willingness to participate in the study?
Describe likely adverse effects of drugs, biologics, devices or procedures participants may encounter while in the study.
Qualitative research - describe ethical issues that could arise while conducting research in the field and strategies you may use to
handle those situations.
Describe any steps to mitigate these risks.
Benefits
Describe potential direct benefits to study participants – including diagnostic or therapeutic, physical, psychological or emotional,
learning benefits. This cannot include incentives or payments.
State if there are no direct benefits.
Describe potential benefits to society and/or general knowledge to be gained.
Describe why potential benefits are reasonable in relation to potential risks. If applicable, justify why risks to vulnerable subjects are
reasonable to potential benefits.
The most common side effects seen with aspirin use are but not limited to nausea, vomiting, heartburn in the mother seen in about
10% of the patients. There is no increased risk for bleeding during antepartum, intrapartum or postpartum period and there are no
known fetal risks with low dose aspirin. There is no risk to the control group involving low risk pregnant women as they do not meet
criteria to receive aspirin during the study or outside of it.
The ultrasound assessments of the uterine and brachial arteries are non-invasive and do not pose any maternal or fetal risks. Patients
may experience discomfort using ultrasound assessment of the brachial artery which involves inflating the blood cuff around the
forearm for 5 minutes. 
Possible side effects from blood draws include redness, swelling, pain or bruising at the blood draw site. There are no maternal or
fetal risks from ultrasound assessments during pregnancy.
There are no identifiable social, legal and economic risks associated with participation in this study.
There is a possibility of direct benefit to the group of patients randomized to receive 162 mg of aspirin as we might see a greater
reduction in the risk preeclampsia. The knowledge gained from this study will potentially help the medical community understand the
pharmacodynamics of aspirin for the prevention of preeclampsia. The information may be further used to tailor women's prenatal care
to improve maternal and fetal outcomes related to the dose of aspirin.
For the experimental groups, there is no known maternal and fetal risks from aspirin use in pregnancy. The control group with low risk
pregnant women will not receive aspirin as they do not meet criteria to receive preeclampsia prophylaxis for the study or outside of it
Section 11 Page 5 of 10
47841


Available Alternative Opportunities/Treatments
Describe alternative treatments or opportunities that might be available to those who choose not to participate in the study, and which
offer the subject equal or greater advantages. If applicable, this should include a discussion of the current standard of care treatment(s).
There are no alternative treatments or procedures if the subjects do not wish to participate in the study. They will however continue to
receive standard prenatal and other indicated care and ultrasounds without being enrolled in this study
Back to Top
Records, Privacy, and Confidentiality
Specify where the data and/or specimens will be stored and how the researcher will ensure the privacy and confidentiality of both.
Specify who will have access to the data/specimens and why they need access.
Describe how data will be managed after the study is complete:
If data/specimens will be maintained, specify whether identifiers will be removed from the maintained information/material.
If identifiers will not be removed, provide justification for retaining them and describe how you will protect confidentiality.
If the data/specimens will be destroyed, verify that this will not violate retention policies and will adhere to applicable facility
requirements.
If this study will use de-identified data from another source, describe what measures will be taken to ensure that subject identifiers are
not given to the investigator.
If applicable, describe procedures for sharing data/specimens with collaborators not affiliated with UK.
For additional considerations: 
Return of Research Results or Incidental Research Findings 
HIPAA policies 
FERPA policies 
Procedures for Transfer agreements 
Information regarding multi-site studies 
NIH Genomic Data Sharing (GDS) Policy 
Digital Data
Research materials include: Socio-demographic patient characteristics, medical chart abstraction, ultrasound assessments of brachial
arterial pressures and uterine artery, blood and urine samples. This information is vital to this study to achieve the objectives outlined
above. For incidental findings affecting the health of a subject, the participant will be contacted via demographic data that was
disclosed at the time of enrollment.
All identifying information will be separated from data and all data will be assigned a coded identification number. Women will be told
during enrollment that all their data will be kept either in a locked file cabinet behind a locked door or on a password protected
computer in the PI's office located in the Chandler Medical Center, Pavilion H, C-369. The data collected during this study will be
maintained for a period of 6 years following the completion of this study. All possible safety measures described above will be initiated
to prevent of breaches of confidentiality.
The urine, blood, cord blood and placental samples collected during the study will be stored in a locked freezer behind locked doors in
Dr. John Bauer's laboratory at the Medical Science building #472. All identifiable information will be removed from the samples. All
information will be de-identified and assigned unique identification codes before storing the specimens. Only the bank staff will have
access to the master list that links the code to you. We will store the coded information in a secured computer behind locked doors.
We will protect the information with passwords/encryption. Encryption changes your information to another format to protect it from
being accessed by anyone outside of the approved staff.
Women will be screened for any history of allergy to aspirin or aspirin related products, history of gastrointestinal or genitourinary
bleeding, history of gastric bypass surgery, peptic ulcer disease or liver dysfunction prior to initiating aspirin to minimize undesirable
side effects of aspirin. Patients on anticoagulant medication(s) will be excluded from this study. A data and safety monitoring plan will
be implemented.
They can choose to leave the study at any time without any consequences to the standard prenatal care they would receive. Risk of
breech of confidentiality - Patients' data will be de-identified and will be assigned a coded identification number. Women will be
informed that their data will be stored in a locked cabinet behind a locked door or on a password protected computer behind a locked
door in the PI's office located in the Chandler Medical Center, Pavilion H, C-369. All possible safety measures will be initiated to
protect patient information. Despite all this, should any breech occur, we will contact patients immediately and work with IRB to correct
any problems
UK IRB policies state that IRB-related research records must be retained for a minimum of 6 years after study closure.
Check this item to confirm that you will retain all IRB-related records for a minimum of 6 years after study closure.
Payment
Describe the incentives (monetary or other) being offered to subjects for their participation. If monetary compensation is offered,
Section 11 Page 6 of 10
47841


indicate the amount and describe the terms and schedule of payment. Please review this guidance for more information on payments to
subjects, including restrictions and expectations.
The subjects will not be offered any incentives for their time during participation in the research study
Costs to Subjects
Include a list of services and/or tests that will not be paid for by the sponsor and/or the study (e.g., MRI, HIV). Keep in mind that a
subject will not know what is “standard” – and thus not covered by the sponsor/study – unless you tell them.
Patients' insurance company, Medicare, or Medicaid will be responsible for the costs of all care and treatment that they would normally
receive for any conditions they may have. These are costs that are considered medically necessary and will be part of the care they
receive even if they do not take part in this study.
The University of Kentucky may not be allowed to bill your insurance company, Medicare, or Medicaid for the medical procedures done
strictly for research. There will be no additional costs to the patients.
There are no funds set aside to pay for the cost of any care or treatment that might be necessary for research related injury or
care.There is no compensation for any wages lost from research related injuries. Medical costs related to care and treatment because
of study-related harm will be the responsibility of the patients
Data and Safety Monitoring
The IRB requires review and approval of data and safety monitoring plans for greater than minimal risk research or NIH-funded/FDA-
regulated clinical investigations.
If you are conducting greater than minimal risk research, or your clinical investigation is NIH-funded, describe your Data and Safety
Monitoring Plan (DSMP). Click here for additional guidance on developing a Data and Safety Monitoring Plan.
If this is a non-sponsored investigator-initiated protocol considered greater than minimal risk research, and if you are planning on
using a Data and Safety Monitoring Board (DSMB) as part of your DSMP, click here for additional guidance for information to
include with your IRB application.
1. Monitoring the progress of clinical investigations and the safety of participants:
Patient selection is facilitated by reviewing electronic health records and patient interviewing only by the authorized personnel in this
study listed in the IRB. The criteria for patient enrollment will be clearly defined to all the study personnel to ensure efficient patient
selection and minimize the risks of ambiguity and deviation from the study protocol. Various systematic reviews of RCTs have not
shown any increased maternal and fetal risks associated with use of low dose aspirin in pregnancy. 
The technique to measure flow mediated dilation has been validated and used extensively in research involving pregnant women.
Patients may experience discomfort at the time of cuff inflation in their forearm for 5 minutes. We will continue to monitor patients
during their hospitalizations and monitor for an increase between groups in adverse maternal and neonatal outcomes as defined as
placental abruption, postpartum hemorrhage, epidural or spinal hematoma, fetal intracranial hemorrhages, premature closure of ductus
or maternal deaths. PI will implement these monitoring procedures and data will be reviewed at 6- month intervals to determine if a
significant increase in adverse events is noted between groups.
2. Assuring compliance with the requirements regarding the reporting of unanticipated problems or adverse experiences:
The PI will review the collected data at regular intervals to determine if adverse maternal or neonatal events are potentially related to
the exposure. If a root cause analysis suggests that the adverse or unanticipated outcome is due to patient’s participation in this
research, then a severe adverse event will promptly be reported to IRB. The patient will also be notified and aspirin dosing will be
changes as needed.
3. Any action resulting in a temporary or permanent suspension of the study is reported to the IRB promptly. This would include but not
limited to a increase in serious maternal and neonatal adverse events as defined above
4. Assuring data accuracy and protocol compliance The PI will monitor data accuracy and protocol compliance
5. Assuring communication among multi-center sites adequately protects the participant (if this is a multi-center study in which the lead
PI or UK is the coordinating institution) - Not applicable
Back to Top
Future Use and Sharing of Material (e.g., Data/Specimens/Information)
If the material collected for this study will be used by members of the research team or shared with other researchers for future studies,
please address the following:
list the biological specimens and/or information that will be kept
briefly describe the types, categories and/or purposes of the future research
describe any risks of the additional use
describe privacy/confidentiality protections that will be put into place
Section 11 Page 7 of 10
47841


describe the period of time specimens/information may be used
describe procedures for sharing specimens/information with secondary researchers
describe the process for, and limitations to, withdrawal of specimens/data
1. list the biological specimens and/or information that will be kept: placenta, cord blood, maternal serum and urine for 2 years after
study closure. Already outlined in previously approved consent. 
2. briefly describe the types, categories and/or purposes of the future research- the mechanistic impact of low dose aspirin on body
functions during pregnancy. 
3. describe any risks of the additional use- None. 
4. describe privacy/confidentiality protections that will be put into place. As outlined in the patient consent, samples are only marked
with study ID and stored in a locked freezer, in a locked lab on UK's campus. 
5. describe the period of time specimens/information may be used. 2 years after study closure. 
6. describe procedures for sharing specimens/information with secondary researchers. All specimens and information sharing has to
be done through the study coordinator, PI and the Director of Maternal Fetal Medicine. Data is stripped of identifiers and is placed in a
excel sheet that is stored behind UK's firewall. It is not planned that we share the information with anyone outside of UK. 
7. describe the process for, and limitations to, withdrawal of specimens/data- Verbally to study staff and then they facilitate the
documentation and level of withdraw (In writing to the PI, from future participation or withdraw of samples and information too)
Are you recruiting or expect to enroll Non-English Speaking Subjects or Subjects from a Foreign Culture? (does not include short
form use for incidentally encountered non-English subjects)
Yes
No
Non-English Speaking Subjects or Subjects from a Foreign Culture
Recruitment and Consent:
Describe how information about the study will be communicated to potential subjects appropriate for their culture, and if necessary,
how new information about the research may be relayed to subjects during the study. 
When recruiting Non-English-speaking subjects, provide a consent document in the subject’s primary language. After saving this
section, attach both the English and translated consent documents in the “Informed Consent" section. 
Cultural and Language Consultants:
The PI is required to identify someone who is willing to serve as the cultural consultant to the IRB.
This person should be familiar with the culture of the subject population and/or be able to verify that translated documents are
the equivalent of the English version of documents submitted.
The consultant should not be involved with the study or have any interest in its IRB approval.
Please include the name, address, telephone number, and email of the person who agrees to be the cultural consultant for
your study.
ORI staff will facilitate the review process with your consultant. Please do not ask them to review your protocol separately.
For more details, see the IRB Application Instructions on Research Involving Non-English Speaking Subjects or Subjects from a
Foreign Culture. 
Local Requirements:
If you will conduct research at an international location, identify and describe:
relevant local regulations
data privacy regulations
applicable laws
ethics review requirements for human subject protection
Please provide links or sources where possible. If the project has been or will be reviewed by a local ethics review board, attach a
copy in the “Additional Information/Materials” section. You may also consult the current edition of the International Compilation of
Human Research Standards
The non-English speaking Hispanic population eligible for this study will be consented by certified Spanish translators listed as
study personnel on this study. The consent form translated to Spanish equivalent to the English version will be provided. The
translators will be present during the entire process of recruitment, consent and follow up prenatal and ultrasound visits.
The patients will be notified during the consenting process that they may choose not to be a study participant without any
consequences to standard prenatal care she would receive
Section 11 Page 8 of 10
47841


Section 11 Page 9 of 10
47841


Does your study involve HIV/AIDS research and/or screening for other reportable diseases (e.g., Hepatitis C, etc…)?
Yes
No
HIV/AIDS Research
If you have questions about what constitutes a reportable disease and/or condition in the state of Kentucky, see ORI’s summary
sheet: “Reporting Requirements for Diseases and Conditions in Kentucky" [PDF].
HIV/AIDS Research: There are additional IRB requirements for designing and implementing the research and for obtaining
informed consent. Describe additional safeguards to minimize risk to subjects in the space provided below.
For additional information, visit the online IRB Survival Handbook to download a copy of the "Medical IRB's requirements for
Protection of Human Subjects in Research Involving HIV Testing" [D65.0000] [PDF], and visit the Office for Human Research
Protections web site for statements on AIDS research, or contact the Office of Research Integrity at 859-257-9428.
PI-Sponsored FDA-Regulated Research
Is this an investigator-initiated study that:
1) involves testing a Nonsignificant Risk (NSR) Device, or
2) is being conducted under an investigator-held Investigational New Drug (IND) or Investigational Device Exemption (IDE)?
Yes
No
PI-Sponsored FDA-Regulated Research
If the answer above is yes, then the investigator assumes the regulatory responsibilities of both the investigator and sponsor. The
Office of Research Integrity provides a summary list of sponsor IND regulatory requirements for drug trials [PDF], IDE regulatory
requirements for SR device trials [PDF], and abbreviated regulatory requirements for NSR device trials [PDF]. For detailed
descriptions see FDA Responsibilities for Device Study Sponsors or FDA Responsibilities for IND Drug Study Sponsor-
Investigators.
Describe the experience/knowledge/training (if any) of the investigator serving as a sponsor (e.g., previously held an
IND/IDE); and
Indicate if any sponsor obligations have been transferred to a commercial sponsor, contract research organization (CRO),
contract monitor, or other entity (provide details or attach FDA 1571).
IRB policy requires mandatory training for investigators who are also FDA-regulated sponsors (see Sponsor-Investigator FAQs).
A sponsor-investigator must complete the applicable Office of Research Integrity web based training, (drug or device) before final
IRB approval is granted.
Has the sponsor-investigator completed the mandatory PI-sponsor training prior to this submission?
Yes
No
If the sponsor-investigator has completed equivalent sponsor-investigator training, submit documentation of the content for the
IRB’s consideration. 
Attachments
Section 11 Page 10 of 10
47841


HIPAA
0 unresolved
comment(s)
Is HIPAA applicable?
Yes
No
(Visit ORI's Health Insurance Portability and Accountability Act (HIPAA) web page to determine if your research falls under the HIPAA
Privacy Regulation.)
I have attached a HIPAA Waiver of Authorization.
Yes
No
Attachments
Section 12 Page 1 of 1
47841


STUDY DRUG INFORMATION
0 unresolved
comment(s)
The term drug may include:
FDA approved drugs,
unapproved use of approved drugs,
investigational drugs or biologics,
other compounds or products intended to affect structure or function of the body, and/or
complementary and alternative medicine products such as dietary supplements, substances generally recognized as safe (GRAS)
when used to diagnose, cure mitigate, treat or prevent disease, or clinical studies of e-cigarettes examining a potential therapeutic
purpose.
Does this protocol involve a drug including an FDA approved drug; unapproved use of an FDA approved drug; and/or an
investigational drug?
Yes
No
If yes, complete the questions below. Additional study drug guidance.
LIST EACH DRUG INVOLVED IN STUDY IN THE SPACE BELOW
Drug Name:
Note: Inpatient studies are required by Hospital Policy to utilize Investigational Drug Service (IDS) pharmacies (Oncology or
Non-Oncology). Use of IDS is highly recommended, but optional for outpatient studies. Outpatient studies not using IDS
services are subject to periodic inspection by the IDS for compliance with drug accountability good clinical practices. 
Indicate where study drug(s) will be housed and managed:
Investigational Drug Service (IDS) UK Hospital
Other Location:
Is the study being conducted under a valid Investigational New Drug (IND) application?
Yes
No
If Yes, list IND #(s) and complete the following:
IND Submitted/Held by:
Sponsor:
Held By:
Investigator:
Held By:
Other:
Held By:
Checkmark if the study is being conducted under FDA’s Expanded Access Program (e.g., Treatment IND)
or if this is an Individual Patient Expanded Access IND (FDA Form 3926).
FDA's Expanded Access Program Information for Individual Patient Expanded Access INDs, and attach the
following:
FDA Form 3926;
FDA expanded access approval or correspondence;
Confirmation of agreement from manufacturer or entity authorized to provide access to the product.
For guidance and reporting requirements at the conclusion of treatment see the Expanded Access SOP.
Complete and attach the required Study Drug Form picking "Study Drug Form" for the document type. Any
Section 13 Page 1 of 2
47841


applicable drug documentation (e.g., Investigator Brochure; approved labeling; publication; FDA correspondence,
etc.) should be attached using "Other Drug Documentation" for the document type.
Attachments
Section 13 Page 2 of 2
47841


STUDY DEVICE INFORMATION
0 unresolved
comment(s)
A DEVICE may be a:
component, part, accessory;
assay, reagent, or in-vitro diagnostic device;
software, digital health, or mobile medical app;
other instrument if intended to affect the structure or function of the body, diagnose, cure, mitigate, treat or prevent disease; or
a homemade device developed by an investigator or other non-commercial entity and not approved for marketing by FDA.
For additional information, helpful resources, and definitions, see ORI's Use of Any Device Being Tested in Research web page.
Does this protocol involve testing (collecting safety or efficacy data) of a medical device including an FDA approved device,
unapproved use of an approved device, humanitarian use device, and/or an investigational device?
Yes
No
[Note: If a marketed device(s) is only being used to elicit or measure a physiologic response or clinical outcome, AND, NO data will
be collected on or about the device itself, you may answer “no” above, save and exit this section, (Examples: a chemo drug study
uses an MRI to measure tumor growth but does NOT assess how effective the MRI is at making the measurement; an exercise study
uses a heart monitor to measure athletic performance but no safety or efficacy information will be collected about the device itself, nor
will the data collected be used for comparative purposes against any other similar device).]
If you answered yes above, please complete the following questions.
LIST EACH DEVICE BEING TESTED IN STUDY IN THE SPACE BELOW
Device Name:
Is the study being conducted under a valid Investigational Device Exemption (IDE),
Humanitarian Device Exemption (HDE) or Compassionate Use?
Yes
No
If Yes, complete the following: 
IDE or HDE #(s)
IDE/HDE Submitted/Held by:
Sponsor:
Held By:
Investigator:
Held By:
Other:
Held By:
 Check if this is a Treatment IDE or Compassionate Use under the Food and Drug Administration (FDA)
Expanded Access program.
For Individual or Small Group Expanded Access, see FDA's Early Expanded Access Program Information,
and attach the following:
FDA expanded access approval or sponsor’s authorization;
An independent assessment from an uninvolved physician, if available;
Confirmation of agreement from manufacturer or entity authorized to provide access to the product.
For guidance and reporting requirements at the conclusion of treatment see the Medical Device SOP.
Section 14 Page 1 of 2
47841


Does the intended use of any research device being tested (not clinically observed) in this study meet the regulatory definition of
Significant Risk (SR) device?
Yes. Device(s) being tested in this study presents a potential for serious risk to the health, safety, or welfare of a subject and
(1) is intended as an implant; or (2) is used in supporting or sustaining human life; or (3) is of substantial importance in
diagnosing, curing, mitigating or treating disease, or otherwise prevents impairment of human health; or (4) otherwise presents
a potential for serious risk to the health, safety, or welfare of a subject.
No. All devices being tested in this study do not present a potential for serious risk to the health, safety, or welfare of
subjects/participants.
Complete and attach the required Study Device Form, picking the "Study Device Form" for the document type. Any
applicable device documentation (e.g., Manufacturer information; patient information packet; approved labeling; FDA
correspondence, etc.) should be attached using "Other Device Documentation" for the document type.
Attachments
Section 14 Page 2 of 2
47841


RESEARCH SITES
0 unresolved
comment(s)
To complete this section, ensure the responses are accurate then click "SAVE".
A) Check all the applicable sites listed below at which the research will be conducted. If none apply, you do not need to check any
boxes.
UK Sites
UK Classroom(s)/Lab(s)
UK Clinics in Lexington
UK Clinics outside of Lexington
UK Healthcare Good Samaritan Hospital
UK Hospital
Schools/Education Institutions
Fayette Co. School Systems *
Other State/Regional School Systems
Institutions of Higher Education (other than UK)
*Fayette Co. School systems, as well as other non-UK
sites, have additional requirements that must be
addressed. See ORI's IRB Application Instructions -
Off-site Research web page for details.
Other Medical Facilities
Bluegrass Regional Mental Health Retardation Board
Cardinal Hill Hospital
Eastern State Hospital
Norton Healthcare
Nursing Homes
Shriner’s Children’s Hospital
Veterans Affairs Medical Center
Other Hospitals and Med. Centers
Correctional Facilities
Home Health Agencies
International Sites
Research activities conducted at performance sites that are not owned or operated by the University of Kentucky (UK) or
at sites that do not fall under the UK IRB’s authority, are subject to special procedures for coordination of research
review. Additional information is required (see IRB Application Instructions - Off-Site Research web page), including:
A letter of support and local context is required from non-UK sites. See Letters of Support and Local Context on the
IRB Application Instructions - Off-Site Research web page for more information.
Supportive documentation, including letters of support, can be attached below.
NOTE: If the non-UK sites or non-UK personnel are engaged in the research, there are additional federal and
university requirements which need to be completed for their participation. For instance, the other site(s) may need
to complete their own IRB review, or a cooperative review arrangement may need to be established with non-UK
sites.
Section 15 Page 1 of 2
47841


Questions about the participation of non-UK sites/personnel should be discussed with the ORI staff at (859) 257-
9428.
List all other non-UK owned/operated locations where the research will be conducted:
Describe the role of any non-UK site(s) or non-UK personnel who will be participating in your research.
Please describe the plan for the management of reporting unanticipated problems, noncompliance, and submission of
protocol modifications and interim results from the non-UK sites:
Attachments
B) If your research involves collaboration with any sites and/or personnel outside the University of Kentucky, then it is considered
multisite research and IRB reliance issues will need to be addressed. This may include national multi-center trials as well local studies
involving sites/personnel external to UK. If you would like to request that the University of Kentucky IRB (UK IRB) serve as the lead
IRB for your study, or if you would like the UK IRB to defer review to another IRB, please contact the IRBReliance@uky.edu.
Section 15 Page 2 of 2
47841


RESEARCH ATTRIBUTES
0 unresolved
comment(s)
Instructions: For various reasons, it is necessary to determine whether your research activities meet the definition
of clinical research and/or a clinical trial. Your responses to the next series of questions will make that
determination. For more details on the definitions, go to ORI’s clinical research vs. clinical trial web page or visit NIH's
decision tree for the NIH Clinical Trial definition. 
My research activities include one or more of the following:
Patient-oriented research regarding mechanisms of human disease, therapeutic interventions, clinical studies, or
development of new technologies
Yes
No
Material of human origin (such as tissues, specimens, and cognitive phenomena) for which an investigator (or colleague)
directly interacts with human subjects
Yes
No
Epidemiologic or Behavioral Studies
Yes
No
Outcomes Research or Health Services Research
Yes
No
Does your research study involve one or more human subjects prospectively assigned into one or more interventions
(which may include placebo or other control) to evaluate the effects of those interventions on health-related biomedical or
behavioral outcomes?
Yes
No
Indicate the items below that apply to your research. Depending on the items applicable to your research, you may be required to
complete additional forms or meet additional requirements. Contact the ORI (859-257-9428) if you have questions about additional
requirements.
Not applicable
Check All That Apply
Academic Degree/Required Research
Alcohol/Drug/Substance Abuse Research
Biological Specimen Bank Creation (for sharing)
Cancer Research
CCTS-Center for Clinical & Translational Science
Certificate of Confidentiality
Collection of Biological Specimens for banking and use
Community-Based Participatory Research
Deception
Educational/Student Records (e.g., GPA, test scores)
Emergency Use (Single Patient)
Gene Transfer
Genetic Research
NIH Genomic Data Sharing (GDS) (databases such as GWAS,
dbGaP, GenBank)
Treatment with Human Cells, Tissues, and Cellular and Tissue
Based Products
Individual Expanded Access or Compassionate Use
International Research
Planned Emergency Research Involving Exception from
For additional requirements and information:
Cancer Research (MCC PRMC)
Certificate of Confidentiality (look up
"Confidentiality/Privacy...")
CCTS (Center for Clinical and Translational
Science)
Clinical Research (look up "What is the definition
of....)
Clinical Trial
Collection of Biological Specimens for Banking
(look up "Specimen/Tissue Collection...")
Collection of Biological Specimens (look up
"Specimen/Tissue Collection...")
Community-Based Participatory Research (look
up "Community-Engaged...")
Data & Safety Monitoring Board (DSMB)
*For Medical IRB: Service Request Form for
CCTS DSMB
Data & Safety Monitoring Plan
Deception*
*For deception research, also go to the E-IRB
Application Informed Consent section,
checkmark and complete "Request for Waiver
of Informed Consent Process"
Emergency Use (Single Patient) [attach
Emergency Use Checklist] (PDF)
Genetic Research (look up "Specimen/Tissue
Section 16 Page 1 of 2
47841


Informed Consent
Recombinant DNA
Registry or data repository creation
Stem Cell Research
Suicide Ideation or Behavior Research
Survey Research
Transplants
Use, storage and disposal of radioactive material and radiation
producing devices
Vaccine Trials
Collection...")
Gene Transfer
HIV/AIDS Research (look up "Reportable
Diseases/Conditions")
Screening for Reportable Diseases [E2.0000]
(PDF)
International Research (look up "International &
Non-English Speaking")
NIH Genomic Data Sharing (GDS) Policy (PDF)
Planned Emergency Research Involving Waiver
of Informed Consent*
*For Planned Emergency Research Involving
Waiver of Informed Consent, also go to the E-
IRB Application Informed Consent section,
checkmark and complete "Request for Waiver
of Informed Consent Process"
Use, storage and disposal of radioactive material
and radiation producing devices
Section 16 Page 2 of 2
47841


FUNDING/SUPPORT
0 unresolved
comment(s)
If the research is being submitted to, supported by, or conducted in cooperation with an external or internal agency or funding program, indicate below
all the categories that apply. 
Not applicable
Check All That Apply
Grant application pending
(HHS) Dept. of Health & Human Services
(NIH) National Institutes of Health
(CDC) Centers for Disease Control & Prevention
(HRSA) Health Resources and Services
Administration
(SAMHSA) Substance Abuse and Mental Health
Services Administration
(DoJ) Department of Justice or Bureau of Prisons
(DoE) Department of Energy
(EPA) Environmental Protection Agency
Federal Agencies Other Than Those Listed Here
Industry (Other than Pharmaceutical Companies)
Internal Grant Program w/ proposal
Internal Grant Program w/o proposal
National Science Foundation
Other Institutions of Higher Education
Pharmaceutical Company
Private Foundation/Association
U.S. Department of Education
State
Click applicable listing(s) for additional requirements and information:
(HHS) Dept. of Health & Human Services
(NIH) National Institutes of Health
(CDC) Centers for Disease Control & Prevention
(HRSA) Health Resources & Services Administration
(SAMHSA) Substance Abuse & Mental Health Services Administration
Industry (Other than Pharmaceutical Companies) [IRB Fee Info]
National Science Foundation
(DoEd) U.S. Department of Education
(DoJ) Department of Justice or Bureau of Prisons 
(DoE) Department of Energy Summary and Department of Energy Identifiable
Information Compliance Checklist
(EPA) Environmental Protection Agency
Other:
Specify the funding source and/or cooperating organization(s) (e.g., National Cancer Institute, Ford Foundation, Eli Lilly & Company, South
Western Oncology Group, Bureau of Prisons, etc.):
 
Add Related Grants
If applicable, please search for and select the OSPA Account number or Electronic Internal Approval Form (eIAF) # (notif #)
associated with this IRB application using the "Add Related Grants" button. 
If required by your funding agency, upload your grant using the "Grant/Contract Attachments" button.
Add Related Grants
Grant/Contract Attachments
The research involves use of Department of Defense (DoD) funding, military personnel, DoD facilities, or other DoD resources. (See DoD SOP
and DoD Summary for details)
Yes
No
Using the “attachments” button (below), attach applicable materials addressing the specific processes described in the DoD SOP.
DOD SOP Attachments
Section 17 Page 1 of 2
47841


Additional Certification: (If your project is federally funded, your funding agency may request an Assurance/ Certification/Declaration of Exemption
form.) Check the following if needed:
Protection of Human Subjects Assurance/Certification/Declaration of Exemption (Formerly Optional Form – 310)
Assurance/Certification Attachments
Section 17 Page 2 of 2
47841


OTHER REVIEW COMMITTEES
0 unresolved
comment(s)
If you check any of the below committees, additional materials may be required with your application submission.
Does your research fall under the purview of any of the other review committees listed below? [If yes, check all that apply and attach
applicable materials using the attachment button at the bottom of your screen.]
Yes
No
Institutional Biosafety Committee
Radiation Safety Committee
Radioactive Drug Research Committee
Markey Cancer Center (MCC) Protocol Review
and Monitoring Committee (PRMC)
Graduate Medical Education Committee (GME)
Office of Medical Education (OME)
Additional Information
Institutional Biosafety Committee (IBC) - Attach required IBC
materials
Radiation Safety Committee (RSC) - For applicability, see
instructions and attach form
Radioactive Drug Research Committee (RDRC)
Markey Cancer Center (MCC) Protocol Review and Monitoring
Committee (PRMC)** - Attach MCC PRMC materials, if any, per
instructions.
Office of Medical Education (OME)
Graduate Medical Education Committee (GME)
Attachments 
** If your study involves cancer research, be sure to select "Cancer Research" in the "Research Attributes"
section. ORI will send your research protocol to the Markey Cancer Center (MCC) Protocol Review and Monitoring
Committee (PRMC). The MCC PRMC is responsible for determining whether the study meets the National Cancer Institute
(NCI) definition of a clinical trial and for issuing documentation to you (the investigator) which confirms either that PRMC
approval has been obtained or that PRMC review is not required. Your IRB application will be processed and reviewed
independently from the PRMC review.
Section 18 Page 1 of 1
47841


ADDITIONAL INFORMATION/MATERIALS
0 unresolved
comment(s)
Do you want specific information inserted into your approval letter?
Yes
No
Approval Letter Details:
If you wish to have specific language included in your approval letter (e.g., serial #, internal tracking identifier, etc…), type that
language in the box below exactly as it should appear in the letter. The text you enter will automatically appear at the top of all
approval letters, identical to how you typed it, until you update it. Don't include instructions or questions to ORI staff as those will
appear in your approval letter. If these details need to be changed for any reason, you are responsible for updating the
content of this field.
Additional Materials:
If you have other materials you would like to include for the IRB's consideration, check all that apply and attach the corresponding
documents using the Attachments button below.
Detailed protocol
Dept. of Health & Human Services (DHHS) approved protocol (such as NIH sponsored Cooperative Group Clinical Trial)
Other Documents
Protocol/Other Attachments
NOTE: Instructions for Dept. of Health & Human Services (DHHS)-approved protocol]
If you have password protected documents, that feature should be disabled prior to uploading to ensure access for IRB review.
To view the materials currently attached to your application, click “All Attachments” on the left menu bar.
Section 19 Page 1 of 1
47841


SIGNATURES (ASSURANCES)
0 unresolved
comment(s)
Introduction
All IRB applications require additional assurances by a Department Chairperson or equivalent (DA), and when applicable, a Faculty
Advisor or equivalent (FA). This signifies the acceptance of certain responsibilities and that the science is meritorious and deserving of
conduct in humans. The person assigned as DA should not also be listed in the Study Personnel section, and the individual assigned
as FA should be listed in the Study Personnel section.
For a list of responsibilities reflected by signing the Assurance Statement, refer to "What does the Department Chairperson’s
Assurance Statement on the IRB application mean?"
For a detailed illustration of how to complete this section, please review the short online video tutorial "Signatures
(Assurance) Section - How to Complete." Otherwise, follow the steps below.
Required Signatures:
Individuals chosen as signees may remove the application from their Inbox without signing the Assurance Statement by
clicking "Return to PI" with a comment about why it is being returned (e.g., specific edits are deemed necessary). 
The PI, and personnel chosen as a contact, will receive an email notification that edits are needed, and can find the draft
application in both the "Draft" folder and the "Signatures Status" folder located in the menu in the left margin of the default
Inbox page. The researcher does not have a 'reply' option to the signee's comments and must make the requested edits
directly in the application, or communicate outside the E-IRB system as to why not. Once the response is finalized, the
researcher must re-visit the "Assurances Required" section to click the "Return to Signee" button for their re-
consideration; the signee will receive an email notification at that time. 
Hover your mouse cursor here for additional instructions.
First
Name
Last
Name
Role
Department
Signee
Return
Comment
Date
Signed
 
 
 
Wendy
Hansen
Department
Authorization
Obstetrics
&
Gynecology
 
11/13/2018
07:52 PM
View/Sign
John
O'Brien
Principal
Investigator
Obstetrics
&
Gynecology
 
11/13/2018
09:25 PM
View/Sign
Department Authorization
 This is to certify that I have reviewed this research protocol and that I attest to the scientific validity and importance of
this study; to the qualifications of the investigator(s) to conduct the project and their time available for the project; that
facilities, equipment, and personnel are adequate to conduct the research; and that continued guidance will be provided
as appropriate. When the principal investigator assumes a sponsor function, the investigator has been notified of the
additional regulatory requirements of the sponsor and by signing the principal investigator Assurance Statement, confirms
he/she can comply with them.
*If the Principal Investigator is also the Chairperson of the department, the Vice Chairperson or equivalent should complete
the "Department Authorization".
**IF APPLICABLE FOR RELIANCE: I attest that the principal investigator has been notified of the regulatory requirements of
both the Reviewing and Relying IRBs, according to the information provided in the E-IRB application. The attached Reliance
Assurance Statement, signed by the principal investigator, confirms that he/she can comply with both sets of IRB
requirements.
Section 20 Page 1 of 2
47841


Principal Investigator’s Assurance Statement
I understand the University of Kentucky's policies concerning research involving human subjects and I agree:
1. To comply with all IRB policies, decisions, conditions, and requirements;
2. To accept responsibility for the scientific and ethical conduct of this research study;
3. To obtain prior approval from the Institutional Review Board before amending or altering the research protocol or
implementing changes in the approved consent/assent form;
4. To report to the IRB in accord with IRB/IBC policy, any adverse event(s) and/or unanticipated problem(s) involving risks to
subjects;
5. To complete, on request by the IRB for Full and Expedited studies, the Continuation/Final Review Forms;
6. To notify the Office of Sponsored Projects Administration (OSPA) and/or the IRB (when applicable) of the development of
any financial interest not already disclosed;
7. Each individual listed as study personnel in this application has received the mandatory human research protections
education (e.g., CITI);
8. Each individual listed as study personnel in this application possesses the necessary experience for conducting research
activities in the role described for this research study.
9. To recognize and accept additional regulatory responsibilities if serving as both a sponsor and investigator for FDA
regulated research.
Furthermore, by checking this box, I also attest that:
I have appropriate facilities and resources for conducting the study;
I am aware of and take full responsibility for the accuracy of all materials submitted to the IRB for review;
If applying for an exemption, I also certify that the only involvement of human subjects in this research study will be in the
categories specified in the Protocol Type: Exemption Categories section.
If applying for an Abbreviated Application (AA) to rely on an external IRB, I understand that certain items above (1, 3, 4, 7-8)
may not apply, or may be altered due to external institutional/IRB policies. I document my agreement with the Principal
Investigator Reliance Assurance Statement by digitally signing this application.
*You will be able to "sign" your assurance after you have sent your application for signatures (use Submission section). Once all
Assurance Statement signatures have been acquired, return to this section to submit your application to ORI. 
Section 20 Page 2 of 2
47841


SUBMISSION INFORMATION
0 unresolved
comment(s)
Each Section/Subsection in the menu on the left must have a checkmark beside it (except this Submission section) indicating the
Section/Subsection has been completed. Otherwise your submission for IRB review and approval cannot be sent to the Office of
Research Integrity/IRB.
If applicable, remember to update the Approval Letter Details text box under the Additional Information section
If your materials require review at a convened IRB meeting which you will be asked to attend, it will be scheduled on the next available
agenda and you will receive a message to notify you of the date.
If you are making a change to an attachment, you need to delete the attachment, upload a highlighted version that contains the changes
(use Document Type of "Highlighted Changes"), and a version that contains the changes without any highlights (use the appropriate
Document Type for the item(s)). Do not delete approved attachments that are still in use.
Your protocol has been submitted.
Section 21 Page 1 of 1
47841


 
Document Type
File Loaded
Document Description
File
Size
Modified
By
Mod Date
ApprovalLetter
ApprovalLetter.pdf
 
0.074
jchine2
4/28/2025
11:16:46 AM
AdditionInfoConsiderations Anticipated fetal risks - Additional
considerations.pdf
Anticipated fetal risks
0.458
asr224
1/24/2019
11:32:56 AM
DataCollection
Data Collection clean copy.docx
Data collection form - clean
copy
0.014
asr224
12/28/2018
12:42:08 PM
DataCollection
Data Collection highlighted copy.docx
Data collection form -
highlighted copy
0.014
asr224
12/28/2018
12:40:28 PM
ResearchProcedures
Research procedures timeline pdf.pdf
 
0.067
asr224
11/13/2018
5:54:05 PM
Download all
Section 22 Page 1 of 1
47841


Protocol Changes
Protocol Number: 47841
Click link to sort Changed Date
Study Personnel Changes:
Status
PPIdentity ProtocolID PersonID RoleInProtocol IsContact LastName FirstName Email
DeptCode RoomBuilding SpeedSort PhoneNum DeptDesc AuthorizedConsent ResponsibilityInProject Degree Rank StatusFlag IsRemoved ModBy ModDate SFI IsPIRN MiddleName
Inserted 1031171
104560
10164730 SP
N
Thompson Katherine
katherine.thompson@uky.edu  
 
 
 
 
N
Data
Analysis/Processing
 
 
P
N
ash231
4/28/2025
10:04:57
AM
N
 
 
Inserted 1031172
104560
12170104 SP
N
Stanton
Victoria
victoria.stanton@uky.edu
 
 
 
 
 
N
Data
Analysis/Processing
 
 
P
N
ash231
4/28/2025
10:05:43
AM
N
 
 
Inserted 1031173
104560
10446600 SP
N
Hawk
Gregory
Greg.Hawk@uky.edu
 
 
 
 
 
N
Data
Analysis/Processing
 
 
P
N
ash231
4/28/2025
10:06:22
AM
N
 
 
ModificationJustification changed by ash231 on 4/28/2025 10:27:14 AM
Greg Hawk , Katie Thompson and Tori Stanton are being added as project assistance for data analysis because they have expertise with the subjects on this protocol.
Section 23 Page 1 of 1
47841


 
Modification Comment by Joanne Hines - ORI to PI on 4/28/2025 10:13:11 AM
Please add the changes being made to "Hawk" - highlighted in study personnel section but not included here.
Section 24 Page 1 of 1
47841


Statistical Analysis Plan NCT03893630 
6/27/2025 
To begin, continuous variables (age, BMI, gestational age at delivery, etc.) will be 
summarized with descriptive statistics (n, mean, standard error); categorical variables 
(e.g., pre-eclampsia, method of conception, etc.) will be summarized with counts and 
percentages. 
  
The primary outcome, difference in uterine artery pulsatility index (PI) will be calculated as 
the difference in PI for each patient between each trimester visit. PI at each visit will be 
calculated by averaging left-side and right-side PIs from each of three (or all available) 
images on each side for each patient using ultrasound technology. For a very limited 
number of images identiﬁed using clinical expertise, the MATLAB code below will be used 
to produce PI values if ultrasound technology is insufficient. 
  
An independent and automated image analysis pipeline will be developed using R to crop 
images and MATLAB to perform image analysis. For each available ultrasound image, an 
estimated mean PI will be calculated as the average of the PI from each analyzable 
waveform. For each patient at each visit, left- and right-side estimates will be obtained 
using the median of the available image-level estimates, since the median is more robust 
to outliers resulting from images that might be difficult to read. Finally, the mean PI for each 
patient at each visit will be calculated using the average of the left- and right-side 
estimates. Means and SDs of these indices will be compared to (1) ensure that there are no 
drastic differences from the values calculated using the ultrasound technology and the 
alternative pipeline, and (2) demonstrate the robustness of the calculated primary 
outcome values.